MEPS HC-231 2021 Medical Conditions
August 2023
Agency for Healthcare Research and Quality
Center for Financing, Access, and Cost Trends
5600 Fishers Lane
Rockville, MD 20857
(301) 427-1406
Table of Contents
A. Data Use Agreement
B. Background
1.0 Household Component
2.0 Medical Provider Component
3.0 Survey Management and Data Collection
C. Technical and Programming Information
1.0 General Information
2.0 Data File Information
2.1 Codebook Structure
2.2 Reserved Codes
2.3 Codebook Format
2.4 Variable Naming
2.5 File Contents
2.5.1 Identifier Variables (DUID-CONDRN)
2.5.2 Medical Condition Variables (AGEDIAG-ICD10CDX)
2.5.3 Utilization Variables (OBCOND - RXCOND)
3.0 Survey Sample Information
3.1 Discussion of Pandemic Effects on Quality of 2021 MEPS Data
3.1.1 Summary
3.1.2 Overview
3.1.3 Data Quality Issues for MEPS in 2021 Directly Associated with Data Quality Concerns for the NHIS and CPS
3.1.4 Modifications to the MEPS HC 2021 Sample Design
3.1.5 Data Quality Issues for MEPS FY 2021
3.1.6 Discussion and Guidance
3.2 Sample Weight (PERWT21F)
3.3 Details on Person Weight Construction
3.3.1 MEPS Panel 23 Weight Development Process
3.3.2 MEPS Panel 24 Weight Development Process
3.3.3 MEPS Panel 25 Weight Development Process
3.3.4 MEPS Panel 26 Weight Development Process
3.3.5 The Final Weight for 2021
3.4 Coverage
3.5 Using MEPS Data for Trend Analysis
4.0 National Health Interview Survey (NHIS)
5.0 Longitudinal Analysis
References
D. Variable-Source Crosswalk
Appendix 1: ICD10CDX and CCSR Condition Code Frequencies
Individual identifiers have been removed from the
micro-data contained in these files. Nevertheless, under sections 308 (d) and
903 (c) of the Public Health Service Act (42 U.S.C. 242m and 42 U.S.C. 299 a-1),
data collected by the Agency for Healthcare Research and Quality (AHRQ) and/or
the National Center for Health Statistics (NCHS) may not be used for any purpose
other than for the purpose for which they were supplied; any effort to determine
the identity of any reported cases is prohibited by law.
Therefore in accordance with the above referenced
Federal Statute, it is understood that:
- No one is to use the data in this data set in any way except
for statistical reporting and analysis; and
- If the identity of any person or establishment should be
discovered inadvertently, then (a) no use will be made of this
knowledge, (b) the Director Office of Management AHRQ will be
advised of this incident, (c) the information that would
identify any individual or establishment will be safeguarded or
destroyed, as requested by AHRQ, and (d) no one else will be
informed of the discovered identity; and
- No one will attempt to link this data set with individually
identifiable records from any data sets other than the Medical
Expenditure Panel Survey or the National Health Interview
Survey. Furthermore, linkage of the Medical Expenditure Panel
Survey and the National Health Interview Survey may not occur
outside the AHRQ Data Center, NCHS Research Data Center (RDC) or
the U.S. Census RDC network.
By using these data you signify your agreement to
comply with the above stated statutorily based requirements with the knowledge
that deliberately making a false statement in any matter within the jurisdiction
of any department or agency of the Federal Government violates Title 18 part 1
Chapter 47 Section 1001 and is punishable by a fine of up to $10,000 or up to 5
years in prison.
The Agency for Healthcare Research and Quality
requests that users cite AHRQ and the Medical Expenditure Panel Survey as the
data source in any publications or research based upon these data.
Return To Table Of Contents
The Medical Expenditure Panel Survey (MEPS) provides
nationally representative estimates of health care use, expenditures, sources of
payment, and health insurance coverage for the U.S. civilian
noninstitutionalized population. The MEPS Household Component (HC) also provides
estimates of respondents’ health status, demographic and socio-economic
characteristics, employment, access to care, and satisfaction with health care.
Estimates can be produced for individuals, families, and selected population
subgroups. The panel design of the survey includes five rounds of interviews
covering two full calendar years. Additional rounds were added in 2020 and 2021,
covering third and fourth years respectively, to compensate for the smaller
number of completed interviews in later panels. These extra rounds provide data
for examining person-level changes in selected variables such as expenditures,
health insurance coverage, and health status. Using computer assisted personal
interviewing (CAPI) technology, information about each household member is
collected, and the survey builds on this information from interview to
interview. All data for a sampled household are reported by a single household
respondent.
The MEPS HC was initiated in 1996. Each year a new
panel of sample households is selected. Because the data collected are
comparable to those from earlier medical expenditure surveys conducted in 1977
and 1987, it is possible to analyze long-term trends. Each annual MEPS HC sample
size is about 15,000 households. Data can be analyzed at either the person or
event level. Data must be weighted to produce national
estimates.
The set of households selected for each panel of the
MEPS HC is a subsample of households participating in the previous year’s
National Health Interview Survey (NHIS) conducted by the National Center for
Health Statistics. The NHIS sampling frame provides a nationally representative
sample of the U.S. civilian noninstitutionalized population. In 2006, the NHIS
implemented a new sample design, which included Asian persons in addition to
households with Black and Hispanic persons in the oversampling of minority
populations. NHIS introduced a new sample design in 2016 that discontinued
oversampling of these minority groups.
Return To Table Of Contents
Upon completion of the household CAPI interview and
obtaining permission from the household survey respondents, a sample of medical
providers are contacted by telephone to obtain information that household
respondents cannot accurately provide. This part of the MEPS is called the
Medical Provider Component (MPC) and information is collected on dates of
visits, diagnosis and procedure codes, charges and payments. The Pharmacy
Component (PC), a subcomponent of the MPC, does not collect charges or diagnosis
and procedure codes but does collect drug detail information, including National
Drug Code (NDC) and medicine name, as well as amounts of payment. The MPC is not
designed to yield national estimates. It is primarily used as an imputation
source to supplement/replace household reported expenditure information.
Return To Table Of Contents
MEPS HC and MPC data are collected under the authority
of the Public Health Service Act. Data are collected under contract with Westat,
Inc. (MEPS HC) and Research Triangle Institute (MEPS MPC). Data sets and summary
statistics are edited and published in accordance with the confidentiality
provisions of the Public Health Service Act and the Privacy Act. The National
Center for Health Statistics (NCHS) provides consultation and technical
assistance.
As soon as data collection and editing are completed,
the MEPS survey data are released to the public in staged releases of micro data
files and tables via the
MEPS website and
datatools.ahrq.gov.
Additional information on MEPS is available from the
MEPS project manager or the MEPS public use data manager at the Center for
Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality,
5600 Fishers Lane, Rockville, MD 20857 (301-427-1406).
Return To Table Of Contents
This documentation describes the data contained in
MEPS Public Use Release HC-231, which is one in a series of public use data
files to be released from the 2021 Medical Expenditure Panel Survey Household
Component (MEPS HC). Released as an ASCII file (with related SAS, SPSS, R, and
Stata programming statements and data user information), and a SAS data set, SAS
transport file, Stata data set, and Excel file, this public use file provides
information on household-reported medical conditions collected on a nationally
representative sample of the civilian noninstitutionalized population of the
United States for calendar year 2021 MEPS HC. The file contains 32 variables and
has a logical record length of 113 with an additional 2-byte carriage
return/line feed at the end of each record.
This documentation offers a brief overview of the
types and levels of data provided and the content and structure of the files. It
contains the following sections:
- Data File Information
- Survey Sample Information
- Merging/Linking MEPS Data Files
- Variable-Source Crosswalk
- Appendix: ICD10CDX and CCSR Condition Code Frequencies
A codebook of all the variables included in the 2021
Medical Conditions File is provided in an accompanying file.
For more information on the MEPS sample design, see
Chowdhury et al. (2019). A copy of the survey instrument used to collect the
information on this file is available on the
MEPS website.
Return To Table Of Contents
This file contains 94,641 records. Each record
represents one current medical condition reported for a household survey
member who resides in an eligible responding household and who has a positive
person or family weight. A condition is defined as current if it is
linked to an event during 2021. Conditions in the Priority Condition Enumeration
(PE) section are asked in the context of “has person ever been told by a doctor
or other health care professional that they have (condition)?” except joint pain
and chronic bronchitis, which ask only about the last 12 months.
Persons with a response of Yes (1) to a priority condition question for whom the
condition is not current as defined above will not have a record for that
condition in this file.
This file consists of MEPS survey data obtained in
Rounds 7, 8, and 9 of Panel 23; Rounds 5, 6, and 7 of Panel 24; Rounds 3, 4, and
5 of Panel 25; and Rounds 1, 2, and 3 of Panel 26, the rounds for the MEPS
panels covering calendar year 2021. 2021 is the first data year to include four
panels of data; Panel 23 was extended to include Rounds 7, 8, and 9 and Panel 24
was extended to include Rounds 6 and 7. In addition, the Panel 24 Round 5
reference period was extended into 2021 instead of ending on 12/31/2020.
For most variables on the file, the codebook provides
both weighted and unweighted frequencies. The exceptions to this are weight
variables and variance estimation variables. Only unweighted frequencies of
these variables are included in the accompanying codebook file. See the Weights
Variables list in Section D, Variable-Source Crosswalk.
Person-level data (e.g., demographic or health
insurance characteristics) from the 2021 MEPS Full Year Consolidated file
(HC-233) can be merged to the records in this file using DUPERSID (see Section
4.0 for details). Since each record represents a single condition reported by a
household respondent, some household members may have multiple medical
conditions and thus will be represented by multiple records on this file. Other
household members may have had no reported medical conditions and thus will have
no records on this file. Still other household members may have had a
reported medical condition that did not meet the criteria above and thus will
have no records on this file. Data from this file also can be merged to 2021
MEPS Event Files (HC-229D through HC-229H) by using the link files provided in
HC-229I. (See HC-229I documentation for details.)
Return To Table Of Contents
The codebook and data file list variables in the
following order:
- Unique person identifiers
- Unique condition identifiers
- Medical condition variables
- Utilization variables
- Weight and variance estimation variables
Note that the person identifier is unique within this
data year.
Return To Table Of Contents
The following reserved code values are used:
Value |
Definition |
-1 INAPPLICABLE |
Question was not asked due to skip pattern |
-7 REFUSED |
Question was asked and respondent refused to answer question |
-8 DK |
Question was asked and respondent did not know answer or the information could not be ascertained |
-15 CANNOT BE COMPUTED |
Value cannot be derived from data |
The value -15 (CANNOT BE COMPUTED) is assigned to MEPS
constructed variables in cases where there is not enough information from the
MEPS instrument to calculate the constructed variables. “Not enough information”
is often the result of skip patterns in the data or from missing information
resulting from MEPS responses of -7 (REFUSED) or -8 (DK). Note that reserved
code -8 includes cases where the information from the question was “not
ascertained” or where the respondent chose “don’t know”.
Return To Table Of Contents
This codebook describes an ASCII data set (although
the data are also being provided in an Excel file, a Stata data set, a SAS data
set, and a SAS transport file), and provides the programming identifiers below
for each variable:
Variable Programming Identifiers
Identifier |
Description |
Name |
Variable name |
Description |
Variable descriptor |
Format |
Number of bytes |
Type |
Type of data: numeric
(indicated by NUM) or character (indicated by
CHAR) |
Start |
Beginning column
position of variable in record |
End |
Ending column position
of variable in record |
Return To Table Of Contents
In general, variable names reflect the content of the
variable, with an 8-character limitation. Edited variables end in an “X” and are
so noted in the variable label. (CONDIDX, which is an encrypted identifier
variable, also ends in an “X”.)
As variable collection, universe, or categories are
altered, the variable name will be appended with “_Myy” to indicate in which
year the alterations took place. Details about these alterations can be found
throughout this document.
Variables contained in this delivery were derived
either from the questionnaire itself or from the CAPI. The source of each
variable is identified in Section D, Variable-Source Crosswalk. Sources for each
variable are indicated in one of three ways: (1) variables derived from CAPI or
assigned in sampling are so indicated; (2) variables collected at one or more
specific questions have those numbers and questionnaire sections indicated in
the “SOURCE” column; and (3) variables constructed from multiple questions using
complex algorithms are labeled “Constructed” in the “SOURCE” column.
Return To Table Of Contents
The definitions of Dwelling Units (DUs) in the MEPS HC
are generally consistent with the definitions employed for the National Health
Interview Survey (NHIS). The Dwelling Unit ID (DUID) is a seven-digit ID number
consisting of a 2-digit panel number followed by a five-digit random number
assigned after the case was sampled for MEPS. A three-digit person number (PID)
uniquely identifies each person within the DU. The variable DUPERSID is the
combination of the variables DUID and PID. IDs begin with a 2-digit panel
number.
CONDN is the condition number and uniquely identifies
each condition reported for an individual. The range on this file for CONDN is
1-901. A CONDN beginning with “9” reflects a condition that was added during the
editing process.
The variable CONDIDX uniquely identifies each
condition (i.e., each record on the file) and is the combination of DUPERSID and
CONDN. CONDIDX has a length of 13 with DUPERSID (10) and CONDN (3) combined.
PANEL is a constructed variable used to specify the
panel number for the interview in which the condition was reported. PANEL will
indicate Panel 23, Panel 24, Panel 25, or Panel 26. The panel number is included
as the first two digits of the DUID and DUPERSID.
CONDRN indicates the round in which the condition was
first reported. For a small number of cases, conditions that actually
began in an earlier round were not reported by respondents until subsequent
rounds of data collection. During file construction, editing was performed for
these cases in order to reconcile the round in which a condition began and the
round in which the condition was first reported.
Return To Table Of Contents
This file contains variables describing medical
conditions reported by respondents in several sections of the MEPS
questionnaire, and all questionnaire sections collecting information about
health provider visits and/or prescription medications (see Variable-Source
Crosswalk in Section D for details).
Priority Conditions and Injuries
Certain conditions were a priori designated as “priority conditions” due to their prevalence, expense, or relevance to policy.
Some of these are long-term, life-threatening conditions, such as cancer,
diabetes, emphysema, high cholesterol, hypertension, ischemic heart disease, and
stroke. Others are chronic, manageable conditions, including arthritis and
asthma. The only mental health condition on the priority conditions list is
attention deficit hyperactivity disorder/attention deficit disorder.
When a condition was first mentioned, respondents were
asked whether it was due to an accident or injury (INJURY=1). Only non-priority
conditions (i.e., conditions reported in a section other than PE) are eligible
to be injuries. The interviewer is prevented from selecting priority conditions
as injuries.
Complete List of Conditions Asked in Priority
Conditions Enumeration Section:
Angina/Angina Pectoris
Arthritis
Asthma
Attention Deficit Hyperactivity Disorder
(ADHD)/Attention Deficit Disorder (ADD)
Cancer/Malignancy
Chronic Bronchitis
Coronary Heart Disease
Diabetes/Sugar Diabetes
Emphysema
Heart Attack/Myocardial Infarction (MI)
High Cholesterol
Hypertension/High Blood Pressure
Joint Pain
Other Heart Disease (not coronary heart disease,
angina, or heart attack)
Stroke/Transient Ischemic Attack (TIA)/Mini-stroke
Age Priority Condition Began
The age of diagnosis (AGEDIAG) was collected for all
priority conditions, except joint pain.
For confidentiality reasons, AGEDIAG is set to Inapplicable (-1) for
cancer conditions.
To ensure confidentiality,
age of diagnosis was top-coded to 85. This corresponds with the
age top-coding in person-level PUFs.
Follow-up Questions for Injuries
When a respondent reported that a condition resulted
from an accident or injury (INJURY=1), respondents were asked during the round
in which the injury was first reported whether the accident/injury occurred at
work (ACCDNWRK). This question was not asked about persons aged 15 and younger;
the condition had ACCDNWRK coded to inapplicable (-1) for those persons.
Sources for Conditions on the MEPS Conditions File
The records on this file correspond with medical
condition records collected by CAPI and stored on a person’s MEPS conditions
roster. Conditions can be added to the MEPS conditions roster in several ways. A
condition can be reported in the Priority Condition Enumeration (PE) section in
which persons are asked if they have been diagnosed with specific conditions.
The condition can be identified as the reason reported by the household
respondent for a particular medical event (hospital stay, outpatient visit,
emergency room visit, home health episode, prescribed medication purchase, or
office-based medical provider visit). Some condition information is collected in
the Medical Provider Component of MEPS. However, since it is not available for
everyone in the sample, it is not used to supplement, replace, or verify
household-reported condition data. Conditions reported in the PE section that
are not current are not included on this file.
Treatment of Data from Rounds Not Occurring in 2021
Prior to the 2008 file, priority conditions reported
during Rounds 1 and 2 of the second year panel were included on the file even if
the conditions were not related to an event or reported as a serious condition
occurring in the second year of the panel. Beginning in 2008, priority
conditions are included on the file only if they are also current conditions.
From 2008-2017, a current condition was defined as a condition linked to an
event or a condition the person was currently experiencing (i.e., a condition
selected in the Condition Enumeration (CE) section). However, starting in Panel
21 Round 5 and Panel 22 Round 3, a current condition is defined only as a
condition linked to a current year event. Conditions from Panel 23 Rounds 6 and
7 as well as Panel 24 Rounds 3-5 and Panel 25 Rounds 1-3 that are not included
in the 2021 file may be available in the 2020 Medical Conditions File if the
person had a positive person or family weight in 2020.
Note: Priority conditions are generally chronic
conditions. Even though a person may not have reported an event in 2021 due to
the condition, analysts should consider that the person may still be
experiencing the condition. If a Panel 25 person reported a priority condition
in Round 1 or 2 and did not have an event for the condition in Round 3, 4, or 5,
the condition will not be included on the 2021 Medical Conditions File.
Similarly: if a Panel 24 person reported a priority condition in Round 1, 2, 3,
or 4 and did not have an event for the condition in Round 5, 6, or 7, or if a
Panel 23 person reported a priority condition in Round 1, 2, 3, 4, 5, or 6 and
did not have an event for the condition in Round 7, 8, or 9, the condition will
not be included on the 2021 Medical Conditions File.
Rounds in Which Conditions Were Reported/Selected
(CRND1 - CRND9)
A set of constructed variables indicates the round in
which the condition was first reported (CONDRN), and the subsequent round(s) in
which the condition was selected (CRND1 - CRND9). The condition may be reported
or selected when the person reports an event that occurred due to the condition.
For example, consider a condition for which CRND1 = 0, CRND2 = 1, and CRND3 = 1.
For non-priority conditions (conditions not asked in the PE section), this
sequence of indicators on a condition record implies that the condition was not
present during Round 1 (CRND1 = 0), was first mentioned during Round 2 (CRND2 =
1, CONDRN = 2), and was selected again during Round 3 (CRND3 = 1). For priority
conditions, this sequence of indicators implies that the condition was reported
in the PE section in Round 1 (CONDRN = 1, CRND1 = 0) but was not connected with
an event until Rounds 2 and 3 (CRND2 = 1, CRND3 = 1). Because priority
conditions are asked in the context of “has person ever been told by a doctor or
other health care professional that they have (condition)?” except joint pain
and chronic bronchitis, which ask only about the last 12 months, a priority
condition might not be selected in the round in which it was first reported. A
condition is current if it is linked to an event that occurred in 2021.
Diagnosis Codes
Medical conditions reported by the Household Component
respondent were recorded by the interviewer using a condition pick-list with
ICD-10-CM codes already assigned to conditions in the list. Reported conditions
not in the pick-list were recorded as verbatim text and then were coded to
ICD-10-CM codes (ICD10CDX) by professional coders.
Coders followed specific guidelines in coding missing
values to the ICD-10-CM diagnosis condition variable when a verbatim text string
could not be matched to an ICD-10-CM code through the pick-list. ICD10CDX was
coded -15 (Cannot be Computed) where the verbatim text fell into one of three
categories: (1) the text indicated that the condition was unknown (e.g., DK);
(2) the text indicated the condition could not be diagnosed by a doctor (e.g.,
doctor doesn’t know); or (3) the specified condition was not codable. If the
text indicated a procedure and the condition associated with the procedure could
be discerned from the text, the condition itself is coded. For example, “cataract surgery” is coded as the condition “other cataract” (ICD10CDX is set
to code “H26”). If the condition could not be discerned (e.g. “outpatient
surgery”), ICD10CDX is set to -15.
In order to preserve confidentiality, all of the
conditions provided on this file have been collapsed to 3-digit diagnosis code
categories rather than the fully-specified ICD-10-CM code. For example, the
ICD10CDX value of J02 “Acute pharyngitis” includes the fully-specified
subclassifications J020 and J029; the value F31 “Bipolar disorder” includes the
fully-specified subclassifications F3110 through F319. Table 1 in Appendix 1
provides unweighted and weighted frequencies for all ICD-10-CM condition code
values reported on the file. Less than 1 percent of the ICD-10-CM codes on this
file were edited further by collapsing two or more 3-digit codes into one
3-digit code. This includes clinically rare conditions that were recoded to
broader codes by clinicians. A condition is determined to be clinically rare if
it appears on the
National Institutes of Health’s list of rare diseases.
For confidentiality purposes, approximately 7% of
ICD-10-CM codes were recoded to -15 (Cannot be Computed) for conditions where
the frequency was fewer than 40 for the total unweighted population in the file
or less than 400,000 for the weighted population. Additional factors used to
determine recoding include age and gender.
In a small number of cases, diagnosis and condition
codes were recoded to -15 (Cannot be Computed) if they denoted a pregnancy for a
person younger than 18 or older than 44. Less than one-tenth of 1 percent of
records were recoded in this manner on the 2021 Medical Conditions file. The
person’s age was determined by linking the 2021 Medical Conditions file to the
2020 and 2021 Population Characteristics File. If the person’s age is under 18
or over 44 in the round in which the condition was reported, the appropriate
condition code was recoded to -15 (Cannot be Computed).
Users should note that because of the design of the
survey, most deliveries (i.e., births) are coded as pregnancies. For more
accurate estimates for deliveries, analysts should use RSNINHOS “Reason Entered
Hospital” found on the Hospital Inpatient Stays Public Use File (HC-229D).
Each year, a few conditions on the final file may fall
below the confidentiality threshold. This is due to the multistage file
development process. The confidentiality recoding is performed on the
preliminary version of the Conditions file each year. This preliminary version
is used in the development of other event PUFs and, in turn, these event PUFs
are used in the development of the final Conditions file. During this process,
some records from the preliminary file are dropped because only records that are
relevant to the current data year are reflected in the final Conditions PUF.
Conditions file data can be merged with the 2021 MEPS
Event Files using the 2021 MEPS Condition-Event Linking file (HC-229I). Because
the conditions have been collapsed to 3-digit diagnosis code categories rather
than the fully-specified ICD-10-CM code, it is possible for there to be
duplicate ICD-10-CM condition codes linked to a single medical event when
different fully-specified conditions are coded to the same 3-digit code.
Conditions were reported in several sections of the HC
questionnaire (see Variable-Source Crosswalk in Section D). Labels for all
values of ICD10CDX, as shown in Table 1 of Appendix 1, are provided in the SAS
programming statements included in this release (see the H231SU.TXT file).
Clinical Classification Software Refined
Clinical Classification Software Refined (CCSR) are
used alongside ICD-10-CM diagnosis codes to group medical conditions into
clinically meaningful categories. Although ICD-10-CM diagnosis codes can map to
multiple CCSR codes, for the purposes of this PUF, one ICD-10-CM diagnosis code
may map to up to three CCSR categories (CCSR1X, CCSR2X, CCSR3X) using the
v2022.2 release of the CCSR for ICD-10-CM diagnoses. The CCSR categories on this
PUF are listed in alphabetical order and do not indicate a primary and secondary
diagnosis. For more information on CCSR, visit the
user guide for CCSR.
For confidentiality purposes, less than 2% of the CCSR
categories were collapsed into a broader code for the appropriate body system
where the frequency was less than 40 for the total unweighted population in the
file or less than 400,000 for the weighted population. For example, BLD001
(Nutritional Anemia), may be recoded to BLD000 (Disease of Blood and Disorders
Involving Immune Mechanism), thus revealing only the body system. Less than 1%
of CCSR codes were recoded to -15 (Cannot be Computed) based on frequencies of
ICD10CDX and CCSR pairs.
Table 2 in Appendix 1 provides unweighted and weighted
frequencies for CCSR combinations reported on the file.
Return To Table Of Contents
The variables OBCOND, OPCOND, HHCOND, IPCOND and
ERCOND indicate that at least one 2021 event can be linked to each condition
record on the current file, i.e., office-based, outpatient, home health,
inpatient hospital stays and emergency room visits. Note that the HHCOND variable
includes all home health types, including informal care, and OBCOND and OPCOND
include telehealth visits. The variable RXCOND is an indicator of any prescribed
medicine purchase associated with the condition.
These event indicators were derived from Expenditure
Event Public Use Files (HC-229G, HC-229F, HC-229H, HC-229D, and HC-229E). Events
associated with conditions include all utilization that occurred between January
1, 2021 and December 31, 2021.
Return To Table Of Contents
The challenges associated with MEPS data collection in
2020 after the onset of the COVID-19 pandemic continued into 2021. The major
modifications to the standard MEPS study design remained in effect, permitting
data to be collected safely but with accompanying concerns related to the
quality of the data obtained. These data quality issues are discussed below. The
suggestion made in the documentation for the 2020 MEPS Full Year Consolidated
PUF data (as well as for most federal major in-person surveys conducted in 2021
and 2020) still holds. Researchers are counseled to take care in the
interpretation of estimates based on data collected from these two calendar
years. This includes the comparison of such estimates to those of other years
and corresponding trend analyses.
Return To Table Of Contents
Section 3.1 of the documentation for the
2020 Full Year Consolidated Data File
provides a general discussion of the impact of the COVID-19 pandemic on several
other major in-person federal surveys as well as on MEPS. In addition, it offers
a detailed look at how MEPS was modified to permit safe data collection and the
development of useful estimates at a time when the way the U.S. health care
system functioned underwent many transformations in order to meet population
needs.
In this corresponding 2021 document, focus is placed
mostly on MEPS data quality in 2021. However, it also includes how data quality
issues related to the two federal surveys most closely connected to it, the
National Health Interview Survey (NHIS) carried out by the National Center for
Health Statistics (NCHS) and the Current Population Survey (CPS) carried out by
the Census Bureau, have an impact on the data quality issues of MEPS.
Specifically, the following discussion describes: 1)
data quality issues experienced by the NHIS and CPS that affect MEPS; 2)
modifications to the MEPS sample design in 2021 due to the continuing pandemic;
and 3) potential data quality issues in the FY 2021 MEPS data related to the
COVID-19 pandemic.
Return To Table Of Contents
Households fielded for Round 1 of MEPS in each year
have been selected as a subsample from among the NHIS responding households from
the prior year. The MEPS first year panel in 2021 was Panel 26. The households
fielded for MEPS in Round 1 of Panel 26 were thus selected from NHIS responding
households in 2020. It is important to note here that the NHIS households
eligible for use in MEPS are restricted to the first three quarters of the NHIS
as the fourth quarter households cannot be made available in time for MEPS data
collection early in the next calendar year.
The onset of the pandemic in 2020 at a national level
took place in mid-March of that year, when the NHIS data collection for the
first quarter of 2020 was virtually completed and that of the second quarter was
about to begin. The NHIS had to make a rapid transition from in-person to
telephone interviewing to attempt to gather NHIS data for the second quarter of
2020. While NCHS was able to make the transition, assessments made by NCHS at
the time indicated a much lower response rate than is typically experienced
during Quarter 2 and the quality of Quarter 2 data was of particular concern.
NCHS thus modified the 2020 NHIS sample design for Quarters 3 and 4. A randomly
selected subsample of the sampled housing units originally selected for fielding
in Quarters 3 and 4 of 2020 was removed from the sample to be fielded. This
reduced sample for Quarters 3 and 4 was then enhanced by randomly selecting
responding households from the 2019 NHIS for interviewing in 2020 as well. In
consideration of the data quality issues and sample design modifications
associated with the 2020 NHIS, the MEPS sample design for FY 2021 was modified,
as discussed shortly below.
The quality of CPS data is always of particular
importance to MEPS as March CPS-ASEC estimates serve as the basis of control
totals for the raking component of the MEPS weighting process. These control
totals incorporate the following demographic variables: age, sex,
race/ethnicity, region, MSA status, educational attainment, and poverty status.
The CPS estimates of educational attainment and poverty status used in the
development of the FY 2021 MEPS PUFs were of particular concern. Evaluations of
these estimates undertaken by the Census Bureau have shown that they suffered
from bias due to survey nonresponse with CPS income estimates being on the high
side and the estimate of those under the poverty threshold being on the low
side. The impact of these CPS estimates on the quality of MEPS estimates has
been carefully considered. The approach used for the 2021 MEPS Full Year
Consolidated PUF sample weights is discussed in Section 3.3.
References (Bramlett et al., 2021; Dahlhamer et al.,
2021; Lau et al, 2021; Rothbaum & Bee, 2021, 2022; Zuvekas & Kashihara, 2021)
discussing the fielding of these surveys during the pandemic and possible bias
concerns, can be found in the References section of this document.
Return To Table Of Contents
The MEPS sample is usually selected from Quarters 1 to 3 of NHIS Panels 1 and 3. However, 2020 NHIS Quarter 2 data quality and sample size issues needed to be considered in planning for selecting and fielding a MEPS sample for 2021. It became clear that it would be prudent to modify the 2021 MEPS sample design for MEPS Panel 26 by replacing 2020 NHIS Quarter 2 with another quarter from 2020 NHIS Panels 2 and 4. Action had to be taken immediately because the MEPS sample selection from NHIS responding households begins in the late summer/early fall of each year.
AHRQ contacted NCHS, reviewing the various issues and asking if responding households in NHIS Panels 2 and 4 from Quarter 1 of 2020 could be made available for MEPS sample selection. Virtually all of these households were interviewed in-person prior to the major onset of the pandemic, so the Quarter 1 response rates for all four NHIS panels were consistent with prior years and the data quality issues associated with the pandemic could be avoided. NCHS was fully supportive of this approach and made NHIS Panels 2 and 4 for Quarter 1 available for use by MEPS. Thus, for MEPS Panel 26, the NHIS responding households subsampled for MEPS were selected among all NHIS responding households in all four NHIS panels in Quarter 1 as well as those responding in Quarter 3 of NHIS Panels 1 and 3.
As an adjunct to this modification, it was decided to
take advantage of the additional PSUs (sampled localities) available from NHIS
Panels 2 and 4 and appearing in the MEPS sample for the first time. State level
estimation is of interest to MEPS, and the added PSUs would serve to increase
the precision of variance estimation for state level estimates. State estimates that would be expected
to benefit the most from these added PSUs were the “middle-sized” states where sample sizes were marginal but usually not enough PSUs for variance estimation. The
largest states already had large sample sizes while precision for the smallest
states would remain low. As a result, from Quarter 1 of 2020 NHIS Panels 2 and 4, the MEPS sample focused on oversampling the “middle-sized” states rather than Asians, Blacks, and Hispanics.
Finally, it was decided to collect 2021 data for nine rounds of Panel 23
and seven rounds of Panel 24, so that these two panels will contribute to
MEPS estimates for four calendar years for Panel 23 and three calendar years for Panel 24. In so doing, the number of respondents
to MEPS will be kept at a relatively high level despite the decline in response
rates due to the pandemic. The MEPS FY 2021 PUF records thus consist of data
obtained from the following MEPS Panels and corresponding rounds: Panel 23,
Rounds 7-9; Panel 24, Rounds 5-7; Panel 25, Rounds 3-5; and Panel 26, Rounds
1-3.
Return To Table Of Contents
Three sources of potential bias were identified for
MEPS for FY 2020: long recall period for Round 6 of Panel 23; switching from
in-person to telephone interviewing which likely had a larger impact on Panel
25; and the impact of CPS bias on the MEPS weights. A number of statistically
significant differences were found between panels for FY 2020. Those findings
are discussed in the documentation for the 2020 Full Year Consolidated PUF.
With this in mind, there were a number of
uncertainties for FY 2021 warranting examination. Would Panel 23 data quality
increase substantially once the issue of an extensive recall period was
eliminated? Would the switching from in-person to telephone interview in Round 1
continue to impact Panel 25 estimates? Since Panel 26 was the first year MEPS
panel in 2021, would Panel 26 estimates tend to be different than those of the
other three panels?
Analyses undertaken to examine the quality of MEPS FY
2021 data appearing on the Consolidated PUF have been focused on the comparison
of health care utilization and health insurance status distribution (some
private insurance, some public insurance, no health insurance) for the MEPS
target population between the panels fielded. These comparisons were undertaken
for the full sample and the three age groups of 0-17, 18-64, and 65+.
Comparisons of health care utilization data for Panel
24 and Panel 23 found no statistically significant differences in any of the
analysis variables, suggesting that Panel 23 data quality increased
substantially once the issue of an extensive recall period was eliminated.
Comparisons of Panel 26 and Panel 24 health care utilization data did not detect
any notable differences among event types of a salient nature.
Similar to FY 2020, comparisons of Panel 25 health
care utilization data with those from other panels found that the difference in
estimates reached statistical significance for several event types, with those
from Panel 25 generally being higher. However, the gap between the Panel 25
estimates and other panels has shown a sizeable decrease, suggesting that the
Panel 25 data quality has improved.
Another set of analyses compared estimates based on
the four panels pooled together using the FY 2021 Consolidated PUF weight
compared to the estimates based on the individual panel data and weights.
Analyses indicated that event estimates combining data from all four panels show
little difference from event estimates of the individual panels.
The analyses undertaken for health insurance status
distribution suggest no major differences between the four panels for the
various event type estimates. Even though slight differences were observed with
Panel 25 (e.g., the distribution associated with the age range 18-64 showed a
higher percentage of all public insurance compared to the other three panels
while those at least 65 years of age showed a lower percentage of some private
insurance compared to the other three panels), no statistically significant
differences were detected.
Return To Table Of Contents
The various actions taken in the development of the
person-level weights for the MEPS FY 2021 Consolidated PUF were designed to
limit the potential for bias in the data due to changes in data collection and
response bias. However, evaluations of MEPS data quality in 2021, consistent
with those of other Federal surveys fielded in 2021, suggest that users of the
MEPS FY 2021 Consolidated PUF should exercise caution when interpreting
estimates and assessing analyses based on these data as well as in comparing
2021 estimates to those of prior years.
Return To Table Of Contents
There is a single full-year person-level weight
(PERWT21F) assigned to each record for each key, in-scope person who responded
to MEPS for the full period of time that they were in-scope during 2021. A key
person was either a member of a responding NHIS household at the time of the
interview or joined a family associated with such a household after being
out-of-scope at the time of the NHIS (the latter circumstance includes newborns
as well as those returning from military service, an institution, or residence
in a foreign country). A person is in-scope whenever they are a member of the
civilian, noninstitutionalized portion of the U.S. population.
Return To Table Of Contents
The person-level weight PERWT21F was developed in
several stages. Preliminary person-level weights for Panel 23, Panel 24, Panel
25, and Panel 26 were first created separately. The weighting process for each
panel included an adjustment for nonresponse over time and calibration to
independent population figures. The calibration was initially accomplished
separately for each panel by raking the corresponding sample weights for those
in-scope at the end of the calendar year to Current Population Survey (CPS)
population estimates based on six variables. The six
variables used in the establishment of the person-level control figures
were: educational attainment of
the reference person (no degree, high school/GED no college or some college,
bachelor’s degree or higher); census region (Northeast, Midwest, South,
West); MSA status (MSA, non-MSA); race/ethnicity (Hispanic; Black, non-Hispanic;
Asian, non-Hispanic; and other); sex; and age. A composite weight was then
formed by multiplying each weight from Panel 23 by the factor .22, each weight
from Panel 24 by the factor .22, each weight from Panel 25 by the factor .25,
and each weight from Panel 26 by the factor .31. The choice of factors reflected
the relative effective sample sizes of the four panels, helping to limit the
variance of estimates obtained from pooling the four samples. Weights for the
2021 Full Year Population Characteristics PUF were then developed by raking the
composite weight to the same set of CPS-based control totals.
The standard approach for establishing the 2021 Full
Year Consolidated PUF weight is as follows. When the poverty status information
derived from income variables becomes available, a final raking is undertaken.
The full sample weight appearing on the Population Characteristics PUF for a
given year is re-raked, establishing control figures reflecting poverty status
rather than educational attainment. Thus, control totals are established using
poverty status (five categories: below poverty, from 100 to 125 percent of
poverty, from 125 to 200 percent of poverty, from 200 to 400 percent of poverty,
at least 400 percent of poverty) as well as the other five variables previously
used in the weight calibration.
Return To Table Of Contents
The person-level weight for MEPS Panel 23 was
developed using the 2020 full-year weight for an individual as a “base” weight
for 2020 survey participants present in 2021. For key, in-scope members who
joined an RU some time in 2021 after being out-of-scope in 2020, the initially
assigned person-level weight was the corresponding 2020 family weight. The
weighting process included an adjustment for person-level nonresponse over
Rounds 8 and 9 as well as raking to population control figures for December 2021
for key, responding persons in-scope on December 31, 2021. These control totals
were derived by scaling back the population distribution obtained from the March
2022 CPS to reflect the December 31, 2021 estimated population total (estimated
based on Census projections for January 1, 2022). Variables used for
person-level raking included: education of the reference person (three
categories: no degree; high school/GED only or some college; Bachelor’s or
higher degree); Census region (Northeast, Midwest, South, West); MSA status
(MSA, non-MSA); race/ethnicity (Hispanic; Black, non-Hispanic; Asian,
non-Hispanic; and other); sex; and age. (It may be noted that for
confidentiality reasons, the MSA status variables are no longer released for
public use.) The final weight for key, responding persons who were not in-scope
on December 31, 2021 but were in-scope earlier in the year was the
nonresponse-adjusted person weight without raking.
The 2020 full-year weight used as the base weight for
Panel 23 was derived from the 2018 MEPS Round 1 weight and reflected adjustment
for nonresponse over the remaining data collection rounds in 2018, 2019, and
2020 as well as raking to the December 2018, December 2019, and December 2020
population control figures.
Return To Table Of Contents
The person-level weight for MEPS Panel 24 was
developed using the 2020 full-year weight for an individual as a “base” weight
for survey participants present in 2021. For key, in-scope members who joined an
RU some time in 2021 after being out-of-scope in 2020, the initially assigned
person-level weight was the corresponding 2020 family weight. The weighting
process included an adjustment for person-level nonresponse over Rounds 6 and 7
as well as raking to the same population control totals for December 2021 used
for the MEPS Panel 23 weights for key, responding persons in-scope on December
31, 2021. The same six variables employed for Panel 23 raking (education level,
census region, MSA status, race/ethnicity, sex, and age) were also used for
Panel 24 raking. Similar to Panel 23, the Panel 24 final weight for key,
responding persons not in-scope on December 31, 2021 but in-scope earlier in the
year was the nonresponse-adjusted person weight without raking.
Note that the 2020 full-year weight that was used as
the base weight for Panel 24 was derived using the 2019 MEPS Round 1 weight and
reflected adjustment for nonresponse over the remaining data collection rounds
in 2019 and 2020 as well as raking to the December 2019 and December 2020
population control figures.
Return To Table Of Contents
The person-level weight for MEPS Panel 25 was
developed using the 2020 full-year weight for an individual as a “base” weight
for survey participants present in 2021.
For key, in-scope members who joined an RU sometime in
2021 after being out-of-scope in 2020, the initially assigned person-level
weight was the corresponding 2020 family weight. The weighting process also
included an adjustment for person-level nonresponse over Rounds 4 and 5 as well
as raking to the same population control figures for December 2021 used for the
MEPS Panels 23 and 24 weights for key, responding persons in-scope on December
31, 2021. The same six variables employed for Panels 23 and 24 raking (education
level, census region, MSA status, race/ethnicity, sex, and age) were also used
for Panel 25 raking. Similar to Panels 23 and 24, the Panel 25 final weight for
key, responding persons not in-scope on December 31, 2021 but in-scope earlier
in the year was the nonresponse-adjusted person weight without raking.
Note that the 2020 full-year weight that was used as
the base weight for Panel 25 was derived using the 2020 MEPS Round 1 weight and
reflected adjustment for nonresponse over the remaining data collection rounds
in 2020 as well as raking to the December 2020 population control figures.
Return To Table Of Contents
The person-level weight for MEPS Panel 26 was
developed using the 2021 MEPS Round 1 person-level weight as a “base” weight.
The MEPS Round 1 weights incorporated the following components: the original
household probability of selection for the NHIS adjusted to reflect the NHIS
subsample reserved for MEPS and an adjustment for NHIS nonresponse, the
probability of selection for MEPS from NHIS, an adjustment for nonresponse at
the dwelling unit level for Round 1, and poststratification to control figures
at the person level obtained from the March CPS of 2021. For key, in-scope
members who joined an RU after Round 1, the Round 1 DU weight served as a “base”
weight.
The weighting process also included an adjustment for
nonresponse over the remaining data collection rounds in 2021 as well as raking
to the same population control figures for December 2021 used for the MEPS Panel
23, Panel 24, and Panel 25 weights for key, responding persons in-scope on
December 31, 2021. The same six variables employed for Panel 23, Panel 24, and
Panel 25 raking (education level of the reference person, census region, MSA
status, race/ethnicity, sex, and age) were also used for Panel 26 raking.
Similar to Panel 23, Panel 24, and Panel 25, the Panel 26 final weight for key,
responding persons who were not in-scope on December 31, 2021 but were in-scope
earlier in the year was the nonresponse-adjusted person weight without raking.
Return To Table Of Contents
The final raking of those in-scope at the end of the
year has been described above. In addition, the composite weights of two groups
of persons who were out-of-scope on December 31, 2021 were adjusted for expected
undercoverage. Specifically, the weights of those who were in-scope some time
during the year, out-of-scope on December 31, and entered a nursing home during
the year and still residing in a nursing home at the end of the year were
poststratified to an estimate of the number of persons who were residents of
Medicare- and Medicaid-certified nursing homes for part of the year
(approximately 3-9 months) during 2014. This estimate was developed from data on
the Minimum Data Set (MDS) of the Center for Medicare and Medicaid Services
(CMS). The weights of persons who died while in-scope were poststratified to
corresponding estimates derived using data obtained from the Centers for Disease
Control and Prevention (CDC), National Center for Health Statistics (NCHS),
Underlying Cause of Death, 2018-2021 on
CDC
WONDER Online Database, released in 2023, the latest
available data at the time. Separate decedent control totals were developed for
the “65 and older” and “under 65” civilian noninstitutionalized populations.
Overall, the weighted population estimate for the
civilian noninstitutionalized population for December 31, 2021 is 327,209,772
(PERWT21F >0 and INSC1231=1). The sum of person-level weights across all persons
assigned a positive person-level weight is 331,249,393.
Return To Table Of Contents
The target population for MEPS in this file is the
2021 U.S. civilian, noninstitutionalized population. However, the MEPS sampled
households are a subsample of the NHIS households interviewed in 2017 (Panel
23), 2018 (Panel 24), 2019 (Panel 25), and 2020 (Panel 26). New households
created after the NHIS interviews for the respective panels and consisting
exclusively of persons who entered the target population after 2017 (Panel 23),
after 2018 (Panel 24), after 2019 (Panel 25), or after 2020 (Panel 26) are not
covered by MEPS. Neither are previously out-of-scope persons who join an
existing household but are unrelated to the current household residents. Persons
not covered by a given MEPS panel thus include some members of the following
groups: immigrants; persons leaving the military; U.S. citizens returning from
residence in another country; and persons leaving institutions. Those not
covered represent a small proportion of the MEPS target population.
Return To Table Of Contents
First, of course, we note that there are uncertainties
associated with 2020 and 2021 data quality as discussed earlier in the data
quality section (Section 3.1). Evaluations of important MEPS estimates suggest
that they are of reasonable quality. Nevertheless, analysts are advised to
exercise caution in interpreting these estimates, particularly in terms of trend
analyses since access to health care was substantially affected by the COVID-19
pandemic as were related factors such as health insurance and employment status
for many people.
MEPS began in 1996, and the utility of the survey for
analyzing health care trends expands with each additional year of data; however,
when examining trends over time using MEPS, the length of time being analyzed
should be considered. In particular, large shifts in survey estimates over short
periods of time (e.g. from one year to the next) that are statistically
significant should be interpreted with caution unless they are attributable to
known factors such as changes in public policy, economic conditions, or MEPS
survey methodology.
With respect to methodological considerations, in 2013
MEPS introduced an effort focused on field procedure changes such as interviewer
training to obtain more complete information about health care utilization from
MEPS respondents with full implementation in 2014. This effort likely resulted
in improved data quality and a reduction in underreporting starting in the
second half of 2013 and throughout 2014 full year files and have had some impact
on analyses involving trends in utilization across years. The changes in the
NHIS sample design in 2016 and 2018 could also potentially affect trend
analyses. The new NHIS sample design is based on more up-to-date information
related to the distribution of housing units across the U.S. As a result, it can
be expected to better cover the full U.S. civilian, noninstitutionalized
population, the target population for MEPS, as well as many of its
subpopulations. Better coverage of the target population helps to reduce the
potential for bias in both NHIS and MEPS estimates.
A significant change to the Conditions file occurred
in 2016 when ICD-10-CM condition codes replaced ICD-9-CM codes. As a result of
this transition, CCS codes were replaced with CCSR codes. Up to three CCSR codes
can be assigned to a single condition on this file; previously, a single CCS code was
assigned to each condition (see Section 2.5.2 for details). Also in 2018, the
inclusion criteria for conditions changed; therefore, fewer conditions are on
the 2018 and later files compared to previous years. See section 2.0 for a
discussion of conditions included on the file.
Another change with the potential to affect trend
analyses involved major modifications to the MEPS instrument design and data
collection process, particularly in the events sections of the instrument. These
were introduced in the Spring of 2018 and thus affected data beginning with
Round 1 of Panel 23, Round 3 of Panel 22, and Round 5 of Panel 21. Since the
Full Year 2017 PUFs were established from data collected in Rounds 1-3 of Panel
22 and Rounds 3-5 of Panel 21, they reflected two different instrument designs.
In order to mitigate the effect of such differences within the same full year
file, the Panel 22 Round 3 data and the Panel 21 Round 5 data were transformed
to make them as consistent as possible with data collected under the previous
design. The changes in the instrument were designed to make the data collection
effort more efficient and easy to administer. In addition, expectations were
that data on some items, such as those related to health care events, would be
more complete with the potential of identifying more events. Increases in
service use reported since the implementation of these changes are consistent
with these expectations. Data users should be aware of possible impacts on
the data and especially trend analyses for these data years due to the design
transition.
Process changes, such as data editing and imputation,
may also affect trend analyses. For example, users should refer to Section
2.5.11 in the 2021 Full Year Consolidated file (HC-233) and, for more detail,
the documentation for the prescription drug file (HC-229A) when analyzing
prescription drug spending over time.
As always, it is recommended that data users review
relevant sections of the documentation for descriptions of these types of
changes that might affect the interpretation of changes over time before
undertaking trend analyses.
Analysts may also wish to consider using statistical
techniques to smooth or stabilize analyses of trends using MEPS data such as
comparing pooled time periods (e.g. 1996-1997 versus 2011-2012), working with
moving averages or using modeling techniques with several consecutive years of
MEPS data to test the fit of specified patterns over time.
Finally, statistical significance tests should be
conducted to assess the likelihood that observed trends are not attributable to
sampling variation. In addition, researchers should be aware of the impact of
multiple comparisons on Type I error. Without making appropriate allowance for
multiple comparisons, undertaking numerous statistical significance tests of
trends increases the likelihood of concluding that a change has taken place when
one has not.
Return To Table Of Contents
Data from this file can be used alone or in
conjunction with other files for different analytic purposes. Each MEPS panel
can also be linked back to the previous years’ National Health Interview Survey
public use data files. For information on MEPS/NHIS link files please see the
AHRQ website.
Return To Table Of Contents
Panel-specific longitudinal files are available for
downloading in the data section of the MEPS website. For all four panels (Panel
23, Panel 24, Panel 25, and Panel 26), the longitudinal file comprises MEPS
survey data obtained in all rounds of the panel and can be used to analyze
changes over the entire length of the panel. For Panel 24, a file representing a
three-year period will also be established and updated to cover four years with
the release of 2022 data. For Panel 23, a file representing a four-year period
will be established. Variables in the file pertaining to survey administration,
demographics, employment, health status, disability days, quality of care,
patient satisfaction, health insurance, and medical care use and expenditures
were obtained from the MEPS full-year Consolidated files from the years covered
by each panel. For more details or to download the data files, please see
Longitudinal Data Files at the
AHRQ website.
Return To Table Of Contents
Bramlett, M.D., Dahlhamer, J.M., & Bose, J. (2021,
September).
Weighting Procedures and Bias Assessment for the 2020
National Health Interview Survey.Centers
for Disease Control and Prevention.
Chowdhury, S.R., Machlin, S.R. & Gwet, K.L.
Sample Designs of the Medical Expenditure Panel Survey Household
Component, 1996-2006 and 2007-2016. Methodology
Report #33. January 2019. Agency for Healthcare Research and Quality, Rockville,
MD.
Cox, B. and Iachan, R. (1987). A Comparison of
Household and Provider Reports of Medical Conditions. Journal of the American
Statistical Association 82(400): 1013-18.
Current Population Survey: 2021 Annual Social and Economic
(ASEC) Supplement. (2021). U.S. Census
Bureau.
Dahlhamer, J.M., Bramlett, M.D., Maitland, A., &
Blumberg, S.J. (2021).
Preliminary evaluation of nonresponse bias due to the COVID-19 pandemic on
National Health Interview Survey estimates, April-June 2020.
National Center for Health Statistics.
Edwards, W. S., Winn, D. M., Kurlantzick, V., et al.
Evaluation of National Health Interview Survey Diagnostic Reporting. National
Center for Health Statistics, Vital Health 2(120). 1994.
Health Care Financing Administration (1980).
International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-CM). Vol. 1. (Department of Health and Human Services Pub. No
(PHS) 80-1260). Department of Health and Human Services: U.S. Public Health
Services.
Johnson, Ayah E., and Sanchez, Maria Elena. (1993), “Household and Medical Reports on Medical Conditions: National Medical
Expenditure Survey.” Journal of Economic and Social Measurement, 19,
199-223.
Lau, D.T., Sosa, P., Dasgupta, N., & He, H. (2021).
Impact of the COVID-19 Pandemic on Public Health Surveillance and Survey Data
Collections in the United States.American Journal of Public Health, 111 (12), pp. 2118-2121.
Rothbaum, J. & Bee, A. (2021, May 3).
Coronavirus Infects Surveys, Too: Survey Nonresponse Bias and
the Coronavirus Pandemic. U.S. Census Bureau.
Rothbaum, J. & Bee, A. (2022, September 13).
How Has the Pandemic Continued to Affect Survey Response? Using
Administrative Data to Evaluate Nonresponse in the 2022 Current Population
Survey Annual Social and Economic Supplement. U.S.
Census Bureau.
Zuvekas, S.H. & Kashihara, D. (2021).
The Impacts of
the COVID-19 Pandemic on the Medical Expenditure Panel Survey.
American Journal of Public Health, 111 (12), pp. 2157-2166.
Return To Table Of Contents
MEPS HC-231: 2021 MEDICAL CONDITIONS
UNIQUE IDENTIFIER VARIABLES
VARIABLE |
LABEL |
SOURCE 1 |
DUID |
Panel # + Encrypted DU
Identifier |
Assigned In Sampling |
PID |
Person Number |
Assigned In Sampling |
DUPERSID |
Person ID (DUID + PID) |
Assigned In Sampling |
CONDN |
Condition Number |
CAPI Derived |
CONDIDX |
Condition ID |
CAPI Derived |
PANEL |
Panel Number |
Constructed |
CONDRN |
Condition Round Number |
CAPI Derived |
Return To Table Of Contents
MEDICAL CONDITION VARIABLES
VARIABLE |
LABEL |
SOURCE 1 |
AGEDIAG |
Age When Diagnosed |
PE section |
CRND1 |
Has Condition
Information In Round 1 |
Constructed |
CRND2 |
Has Condition
Information In Round 2 |
Constructed |
CRND3 |
Has Condition
Information In Round 3 |
Constructed |
CRND4 |
Has Condition
Information In Round 4 |
Constructed |
CRND5 |
Has Condition
Information In Round 5 |
Constructed |
CRND6 |
Has Condition
Information In Round 6 |
Constructed |
CRND7 |
Has Condition
Information In Round 7 |
Constructed |
CRND8 |
Has Condition
Information In Round 8 |
Constructed |
CRND9 |
Has Condition
Information In Round 9 |
Constructed |
INJURY |
Was Condition Due To
Accident/Injury |
AH80 |
ACCDNWRK |
Did Accident Occur At
Work |
AH90 |
ICD10CDX |
ICD-10-CM Code For
Condition Edited |
HS40, ER30, OP60,
MV70, HH80, PM120, PE Section (Edited) |
CCSR1X |
Clinical
Classification Refined Code 1 Edited |
HS40, ER30, OP60,
MV70, HH80, PM120, PE section (Edited) |
CCSR2X |
Clinical
Classification Refined Code 2 Edited |
HS40, ER30, OP60,
MV70, HH80, PM120, PE section (Edited) |
CCSR3X |
Clinical
Classification Refined Code 3 Edited |
HS40, ER30, OP60,
MV70, HH80, PM120,
PE section (Edited) |
Return To Table Of Contents
UTILIZATION VARIABLES
VARIABLE |
LABEL |
SOURCE 1 |
HHCOND |
# Any Home Health Events Assoc. w/ Condition? |
Constructed |
IPCOND |
# Any Inpatient Events Assoc. w/ Condition? |
Constructed |
OPCOND |
# Any Outpatient Events Assoc. w/ Condition? |
Constructed |
OBCOND |
# Any Office-Based Events Assoc w/ Condition? |
Constructed |
ERCOND |
# Any ER Events Assoc. w/ Condition? |
Constructed |
RXCOND |
# Any Prescribed Medicines Assoc. w/ Cond.? |
Constructed |
Return To Table Of Contents
WEIGHTS AND VARIANCE ESTIMATION VARIABLES
VARIABLE |
LABEL |
SOURCE 1 |
PERWT21F |
Expenditure File
Person Weight, 2021 |
Constructed |
VARSTR |
Variance Estimation
Stratum, 2021 |
Constructed |
VARPSU |
Variance Estimation
PSU, 2021 |
Constructed |
1See the Household Component section under Survey Questionnaires on the MEPS home page for information on the MEPS HC questionnaire sections shown in the Source column (e.g., PE).
Return To Table Of Contents
Table 1 UNWEIGHTED AND WEIGHTED COUNT OF RECORDS FOR EACH VALUE OF ICD10CDX
ICD10CDX VALUE |
ICD10CDX LABEL |
UNWEIGHTED |
WEIGHTED BY perwt21f |
-15 |
CANNOT BE COMPUTED |
7537 |
82120479.15 |
A08 |
VIRAL AND OTHER
SPECIFIED INTESTINAL INFECTIONS |
89 |
1095817.67 |
A09 |
INFECTIOUS
GASTROENTERITIS AND COLITIS, UNSPECIFIED |
42 |
504042.34 |
A49 |
BACTERIAL INFECTION OF
UNSPECIFIED SITE |
106 |
1350364.55 |
B00 |
HERPESVIRAL [HERPES
SIMPLEX] INFECTIONS |
134 |
1395652.46 |
B02 |
ZOSTER [HERPES ZOSTER] |
146 |
1368707.73 |
B07 |
VIRAL WARTS |
99 |
1339106.17 |
B34 |
VIRAL INFECTION OF
UNSPECIFIED SITE |
86 |
1227954.76 |
B35 |
DERMATOPHYTOSIS |
193 |
2023551.28 |
B37 |
CANDIDIASIS |
117 |
1391194.83 |
B99 |
OTHER AND UNSPECIFIED
INFECTIOUS DISEASES |
47 |
469334.17 |
C18 |
MALIGNANT NEOPLASM OF
COLON |
80 |
728579.32 |
C34 |
MALIGNANT NEOPLASM OF
BRONCHUS AND LUNG |
95 |
913489.91 |
C43 |
MALIGNANT MELANOMA OF
SKIN |
159 |
1670148.65 |
C44 |
OTHER AND UNSPECIFIED
MALIGNANT NEOPLASM OF SKIN |
497 |
4965827.64 |
C50 |
MALIGNANT NEOPLASM OF
BREAST |
256 |
2226561.45 |
C61 |
MALIGNANT NEOPLASM OF
PROSTATE |
210 |
2134646.69 |
C73 |
MALIGNANT NEOPLASM OF
THYROID GLAND |
65 |
719299.61 |
C85 |
OTH AND UNSPECIFIED
TYPES OF NON-HODGKIN LYMPHOMA |
42 |
460143.76 |
C95 |
LEUKEMIA OF
UNSPECIFIED CELL TYPE |
67 |
597101.42 |
D04 |
CARCINOMA IN SITU OF
SKIN |
117 |
1249690.30 |
D22 |
MELANOCYTIC NEVI |
92 |
1095152.07 |
D48 |
NEOPLASM OF UNCERTAIN
BEHAVIOR OF OTHER AND UNSP SITES |
60 |
822449.74 |
D49 |
NEOPLASMS OF
UNSPECIFIED BEHAVIOR |
180 |
1985023.62 |
D50 |
IRON DEFICIENCY ANEMIA |
104 |
1022061.64 |
D64 |
OTHER ANEMIAS |
178 |
1689988.74 |
E03 |
OTHER HYPOTHYROIDISM |
1099 |
12068765.72 |
E04 |
OTHER NONTOXIC GOITER |
127 |
1252425.60 |
E05 |
THYROTOXICOSIS
[HYPERTHYROIDISM] |
174 |
1891924.55 |
E06 |
THYROIDITIS |
87 |
1091467.93 |
E07 |
OTHER DISORDERS OF
THYROID |
629 |
5852893.31 |
E11 |
TYPE 2 DIABETES
MELLITUS |
3025 |
27819255.92 |
E28 |
OVARIAN DYSFUNCTION |
47 |
762111.80 |
E29 |
TESTICULAR DYSFUNCTION |
52 |
568071.38 |
E34 |
OTHER ENDOCRINE
DISORDERS |
110 |
1272144.99 |
E53 |
DEFICIENCY OF OTHER B
GROUP VITAMINS |
103 |
1095753.47 |
E55 |
VITAMIN D DEFICIENCY |
458 |
4819430.24 |
E58 |
DIETARY CALCIUM
DEFICIENCY |
56 |
513223.23 |
E61 |
DEFICIENCY OF OTHER
NUTRIENT ELEMENTS |
181 |
1680059.10 |
E66 |
OVERWEIGHT AND OBESITY |
167 |
1758565.50 |
E78 |
DISORDERS OF
LIPOPROTEIN METABOLISM AND OTHER LIPIDEMIAS |
5010 |
48579855.91 |
E86 |
VOLUME DEPLETION |
83 |
748657.59 |
E87 |
OTHER DISORDERS OF
FLUID, ELECTROLYTE AND ACID-BASE BALANCE |
387 |
3217922.47 |
F03 |
UNSPECIFIED DEMENTIA |
109 |
970174.81 |
F10 |
ALCOHOL RELATED
DISORDERS |
49 |
595371.61 |
F19 |
OTHER PSYCHOACTIVE
SUBSTANCE RELATED DISORDERS |
44 |
465718.57 |
F20 |
SCHIZOPHRENIA |
82 |
680727.38 |
F31 |
BIPOLAR DISORDER |
310 |
2848383.61 |
F32 |
MAJOR DEPRESSIVE
DISORDER, SINGLE EPISODE |
2175 |
23268343.85 |
F34 |
PERSISTENT MOOD
[AFFECTIVE] DISORDERS |
61 |
649514.63 |
F39 |
UNSPECIFIED MOOD
[AFFECTIVE] DISORDER |
69 |
665355.70 |
F41 |
OTHER ANXIETY
DISORDERS |
2547 |
28918769.46 |
F42 |
OBSESSIVE-COMPULSIVE
DISORDER |
57 |
751547.48 |
F43 |
REACTION TO SEVERE
STRESS, AND ADJUSTMENT DISORDERS |
542 |
5834748.31 |
F80 |
SPECIFIC DEVELOPMENTAL
DISORDERS OF SPEECH AND LANGUAGE |
63 |
802184.54 |
F84 |
PERVASIVE
DEVELOPMENTAL DISORDERS |
112 |
1344415.99 |
F90 |
ATTENTION-DEFICIT
HYPERACTIVITY DISORDERS |
744 |
9744563.95 |
F91 |
CONDUCT DISORDERS |
43 |
496735.14 |
F99 |
MENTAL DISORDER, NOT
OTHERWISE SPECIFIED |
259 |
2741775.75 |
G20 |
PARKINSON’S DISEASE |
70 |
779692.26 |
G25 |
OTHER EXTRAPYRAMIDAL
AND MOVEMENT DISORDERS |
178 |
1627590.90 |
G30 |
ALZHEIMER’S DISEASE |
59 |
520373.54 |
G35 |
MULTIPLE SCLEROSIS |
71 |
829176.76 |
G40 |
EPILEPSY AND RECURRENT
SEIZURES |
140 |
1715215.85 |
G43 |
MIGRAINE |
556 |
6368181.38 |
G45 |
TRANSIENT CEREBRAL
ISCHEMIC ATTACKS AND RELATED SYNDROMES |
350 |
3037137.78 |
G47 |
SLEEP DISORDERS |
1550 |
15214610.93 |
G56 |
MONONEUROPATHIES OF
UPPER LIMB |
136 |
1530217.39 |
G57 |
MONONEUROPATHIES OF
LOWER LIMB |
126 |
1197632.07 |
G58 |
OTHER MONONEUROPATHIES |
70 |
678459.10 |
G62 |
OTHER AND UNSPECIFIED
POLYNEUROPATHIES |
344 |
3123390.75 |
G89 |
PAIN, NOT ELSEWHERE
CLASSIFIED |
392 |
3691649.98 |
H04 |
DISORDERS OF LACRIMAL
SYSTEM |
309 |
2913606.62 |
H10 |
CONJUNCTIVITIS |
61 |
851151.08 |
H26 |
OTHER CATARACT |
764 |
6634104.39 |
H33 |
RETINAL DETACHMENTS
AND BREAKS |
84 |
829812.06 |
H35 |
OTHER RETINAL
DISORDERS |
325 |
2983271.78 |
H40 |
GLAUCOMA |
555 |
5013149.20 |
H43 |
DISORDERS OF VITREOUS
BODY |
53 |
496586.38 |
H44 |
DISORDERS OF GLOBE |
100 |
1032961.66 |
H52 |
DISORDERS OF
REFRACTION AND ACCOMMODATION |
418 |
5219342.11 |
H53 |
VISUAL DISTURBANCES |
129 |
1288298.60 |
H54 |
BLINDNESS AND LOW
VISION |
167 |
1746782.41 |
H57 |
OTHER DISORDERS OF EYE
AND ADNEXA |
250 |
2481520.58 |
H61 |
OTHER DISORDERS OF
EXTERNAL EAR |
135 |
1483003.04 |
H66 |
SUPPURATIVE AND
UNSPECIFIED OTITIS MEDIA |
379 |
4942547.98 |
H91 |
OTHER AND UNSPECIFIED
HEARING LOSS |
324 |
3363277.00 |
H92 |
OTALGIA AND EFFUSION
OF EAR |
66 |
878513.67 |
H93 |
OTHER DISORDERS OF
EAR, NOT ELSEWHERE CLASSIFIED |
97 |
1101606.85 |
I10 |
ESSENTIAL (PRIMARY)
HYPERTENSION |
6593 |
62946340.94 |
I20 |
ANGINA PECTORIS |
163 |
1678109.84 |
I21 |
ACUTE MYOCARDIAL
INFARCTION |
511 |
4769298.65 |
I25 |
CHRONIC ISCHEMIC HEART
DISEASE |
858 |
7871245.97 |
I26 |
PULMONARY EMBOLISM |
68 |
700268.15 |
I34 |
NONRHEUMATIC MITRAL
VALVE DISORDERS |
53 |
597308.80 |
I38 |
ENDOCARDITIS, VALVE
UNSPECIFIED |
121 |
1243622.07 |
I48 |
ATRIAL FIBRILLATION
AND FLUTTER |
456 |
4492409.88 |
I49 |
OTHER CARDIAC
ARRHYTHMIAS |
353 |
3334327.96 |
I50 |
HEART FAILURE |
208 |
1745406.48 |
I51 |
COMPLICATIONS AND
ILL-DEFINED DESCRIPTIONS OF HEART DISEASE |
274 |
2442546.72 |
I63 |
CEREBRAL INFARCTION |
61 |
446907.01 |
I73 |
OTHER PERIPHERAL
VASCULAR DISEASES |
55 |
547698.26 |
I74 |
ARTERIAL EMBOLISM AND
THROMBOSIS |
356 |
3261653.40 |
I83 |
VARICOSE VEINS OF
LOWER EXTREMITIES |
50 |
669244.18 |
I87 |
OTHER DISORDERS OF
VEINS |
41 |
429358.25 |
I95 |
HYPOTENSION |
77 |
822389.89 |
I99 |
OTHER AND UNSPECIFIED
DISORDERS OF CIRCULATORY SYSTEM |
92 |
717184.50 |
J00 |
ACUTE NASOPHARYNGITIS
[COMMON COLD] |
265 |
3262368.55 |
J02 |
ACUTE PHARYNGITIS |
307 |
4100371.38 |
J06 |
ACUTE UPPER RESP
INFECTIONS OF MULTIPLE AND UNSP SITES |
101 |
1249254.55 |
J11 |
INFLUENZA DUE TO
UNIDENTIFIED INFLUENZA VIRUS |
158 |
1691895.02 |
J18 |
PNEUMONIA, UNSPECIFIED
ORGANISM |
279 |
2843204.02 |
J20 |
ACUTE BRONCHITIS |
46 |
509665.71 |
J30 |
VASOMOTOR AND ALLERGIC
RHINITIS |
989 |
10874173.45 |
J32 |
CHRONIC SINUSITIS |
518 |
6808221.11 |
J34 |
OTHER AND UNSPECIFIED
DISORDERS OF NOSE AND NASAL SINUSES |
174 |
1738081.13 |
J39 |
OTHER DISEASES OF
UPPER RESPIRATORY TRACT |
80 |
887660.30 |
J40 |
BRONCHITIS, NOT
SPECIFIED AS ACUTE OR CHRONIC |
173 |
1869410.08 |
J42 |
UNSPECIFIED CHRONIC
BRONCHITIS |
147 |
1094523.70 |
J43 |
EMPHYSEMA |
162 |
1230571.30 |
J44 |
OTHER CHRONIC
OBSTRUCTIVE PULMONARY DISEASE |
389 |
3151056.50 |
J45 |
ASTHMA |
1824 |
18827277.46 |
J98 |
OTHER RESPIRATORY
DISORDERS |
207 |
2449636.59 |
K04 |
DISEASES OF PULP AND
PERIAPICAL TISSUES |
158 |
1682305.02 |
K08 |
OTHER DISORDERS OF
TEETH AND SUPPORTING STRUCTURES |
287 |
3258788.65 |
K13 |
OTHER DISEASES OF LIP
AND ORAL MUCOSA |
56 |
561381.61 |
K21 |
GASTRO-ESOPHAGEAL
REFLUX DISEASE |
1791 |
17582843.36 |
K22 |
OTHER DISEASES OF
ESOPHAGUS |
75 |
800711.66 |
K25 |
GASTRIC ULCER |
70 |
581823.17 |
K29 |
GASTRITIS AND
DUODENITIS |
137 |
982639.64 |
K30 |
FUNCTIONAL DYSPEPSIA |
229 |
2257958.25 |
K31 |
OTHER DISEASES OF
STOMACH AND DUODENUM |
157 |
1383889.17 |
K44 |
DIAPHRAGMATIC HERNIA |
72 |
699733.01 |
K46 |
UNSPECIFIED ABDOMINAL
HERNIA |
158 |
1585789.27 |
K50 |
CROHN’S DISEASE
[REGIONAL ENTERITIS] |
57 |
718287.99 |
K52 |
OTHER AND UNSP
NONINFECTIVE GASTROENTERITIS AND COLITIS |
59 |
475886.99 |
K57 |
DIVERTICULAR DISEASE
OF INTESTINE |
100 |
895385.63 |
K58 |
IRRITABLE BOWEL
SYNDROME |
118 |
1135443.95 |
K59 |
OTHER FUNCTIONAL
INTESTINAL DISORDERS |
324 |
3160806.68 |
K63 |
OTHER DISEASES OF
INTESTINE |
209 |
2105001.53 |
K64 |
HEMORRHOIDS AND
PERIANAL VENOUS THROMBOSIS |
85 |
835691.73 |
K76 |
OTHER DISEASES OF
LIVER |
121 |
1149295.87 |
K80 |
CHOLELITHIASIS |
56 |
517791.25 |
K82 |
OTHER DISEASES OF
GALLBLADDER |
92 |
925490.19 |
K92 |
OTHER DISEASES OF
DIGESTIVE SYSTEM |
156 |
1511371.70 |
L02 |
CUTANEOUS ABSCESS,
FURUNCLE AND CARBUNCLE |
64 |
683797.73 |
L03 |
CELLULITIS AND ACUTE
LYMPHANGITIS |
92 |
1009307.47 |
L08 |
OTHER LOCAL INFECTIONS
OF SKIN AND SUBCUTANEOUS TISSUE |
203 |
2222606.37 |
L23 |
ALLERGIC CONTACT
DERMATITIS |
124 |
1441216.74 |
L29 |
PRURITUS |
70 |
745722.11 |
L30 |
OTHER AND UNSPECIFIED
DERMATITIS |
278 |
3712889.32 |
L40 |
PSORIASIS |
135 |
1526470.16 |
L60 |
NAIL DISORDERS |
236 |
2348119.45 |
L65 |
OTHER NONSCARRING HAIR
LOSS |
61 |
661654.94 |
L70 |
ACNE |
276 |
4154816.83 |
L71 |
ROSACEA |
95 |
1089456.46 |
L72 |
FOLLICULAR CYSTS OF
SKIN AND SUBCUTANEOUS TISSUE |
118 |
1385996.86 |
L81 |
OTHER DISORDERS OF
PIGMENTATION |
46 |
626358.70 |
L84 |
CORNS AND CALLOSITIES |
61 |
558858.18 |
L91 |
HYPERTROPHIC DISORDERS
OF SKIN |
55 |
676094.51 |
L98 |
OTH DISORDERS OF SKIN,
SUBCU, NOT ELSEWHERE CLASSIFIED |
452 |
5044722.48 |
M06 |
OTHER RHEUMATOID
ARTHRITIS |
486 |
4049192.94 |
M10 |
GOUT |
386 |
3902358.47 |
M17 |
OSTEOARTHRITIS OF KNEE |
156 |
1459867.21 |
M19 |
OTHER AND UNSPECIFIED
OSTEOARTHRITIS |
1811 |
16151291.76 |
M21 |
OTHER ACQUIRED
DEFORMITIES OF LIMBS |
85 |
921989.38 |
M25 |
OTHER JOINT DISORDER,
NOT ELSEWHERE CLASSIFIED |
1886 |
19060300.18 |
M32 |
SYSTEMIC LUPUS
ERYTHEMATOSUS (SLE) |
80 |
764443.28 |
M35 |
OTHER SYSTEMIC
INVOLVEMENT OF CONNECTIVE TISSUE |
66 |
689645.80 |
M41 |
SCOLIOSIS |
121 |
1401465.77 |
M43 |
OTHER DEFORMING
DORSOPATHIES |
51 |
523137.53 |
M48 |
OTHER SPONDYLOPATHIES |
126 |
1202520.23 |
M50 |
CERVICAL DISC
DISORDERS |
60 |
592988.79 |
M51 |
THORACIC, THORACOLUM,
AND LUMBOSACRAL INTVRT DISC DISORDERS |
409 |
4210966.50 |
M53 |
OTHER AND UNSPECIFIED
DORSOPATHIES, NOT ELSEWHERE CLASSIFIED |
245 |
2450238.66 |
M54 |
DORSALGIA |
1836 |
19101011.35 |
M62 |
OTHER DISORDERS OF
MUSCLE |
313 |
3198975.40 |
M65 |
SYNOVITIS AND
TENOSYNOVITIS |
81 |
794088.64 |
M71 |
OTHER BURSOPATHIES |
55 |
620072.11 |
M72 |
FIBROBLASTIC DISORDERS |
104 |
1153597.37 |
M75 |
SHOULDER LESIONS |
203 |
2070882.64 |
M77 |
OTHER ENTHESOPATHIES |
155 |
1663236.17 |
M79 |
OTH AND UNSP SOFT
TISSUE DISORDERS, NOT ELSEWHERE CLASSIFIED |
1141 |
11051403.52 |
M81 |
OSTEOPOROSIS WITHOUT
CURRENT PATHOLOGICAL FRACTURE |
274 |
2483407.86 |
M85 |
OTHER DISORDERS OF
BONE DENSITY AND STRUCTURE |
248 |
2353303.51 |
M89 |
OTHER DISORDERS OF
BONE |
70 |
509599.67 |
N15 |
OTHER RENAL
TUBULO-INTERSTITIAL DISEASES |
49 |
507852.21 |
N18 |
CHRONIC KIDNEY DISEASE
(CKD) |
66 |
639699.72 |
N19 |
UNSPECIFIED KIDNEY
FAILURE |
93 |
742830.54 |
N20 |
CALCULUS OF KIDNEY AND
URETER |
224 |
2459467.27 |
N28 |
OTH DISORDERS OF
KIDNEY AND URETER, NOT ELSEWHERE CLASSIFIED |
341 |
2912870.50 |
N30 |
CYSTITIS |
106 |
927423.02 |
N32 |
OTHER DISORDERS OF
BLADDER |
203 |
2071200.69 |
N39 |
OTHER DISORDERS OF
URINARY SYSTEM |
779 |
8019554.24 |
N40 |
BENIGN PROSTATIC
HYPERPLASIA |
394 |
3953015.47 |
N42 |
OTHER AND UNSPECIFIED
DISORDERS OF PROSTATE |
183 |
1797378.62 |
N52 |
MALE ERECTILE
DYSFUNCTION |
110 |
1387973.15 |
N60 |
BENIGN MAMMARY
DYSPLASIA |
45 |
474015.18 |
N63 |
UNSPECIFIED LUMP IN
BREAST |
76 |
778362.45 |
N64 |
OTHER DISORDERS OF
BREAST |
50 |
594068.57 |
N76 |
OTHER INFLAMMATION OF
VAGINA AND VULVA |
42 |
492605.55 |
N81 |
FEMALE GENITAL
PROLAPSE |
46 |
430268.08 |
N83 |
NONINFLAMMATORY DISORD
OF OVARY, FALLOP AND BROAD LIGAMENT |
64 |
815388.28 |
N89 |
OTHER NONINFLAMMATORY
DISORDERS OF VAGINA |
57 |
609149.17 |
N92 |
EXCESSIVE, FREQUENT
AND IRREGULAR MENSTRUATION |
117 |
1590896.34 |
N94 |
PAIN AND OTH COND
ASSOC W FEM GNTL ORG AND MENSTRUAL CYCLE |
57 |
846175.75 |
N95 |
MENOPAUSAL AND OTHER
PERIMENOPAUSAL DISORDERS |
183 |
2062187.86 |
R00 |
ABNORMALITIES OF HEART
BEAT |
246 |
2587015.92 |
R01 |
CARDIAC MURMURS AND
OTHER CARDIAC SOUNDS |
127 |
1296350.93 |
R03 |
ABNORMAL
BLOOD-PRESSURE READING, WITHOUT DIAGNOSIS |
60 |
592844.86 |
R05 |
COUGH |
258 |
2901065.40 |
R06 |
ABNORMALITIES OF
BREATHING |
305 |
2980856.39 |
R07 |
PAIN IN THROAT AND
CHEST |
212 |
2154975.68 |
R09 |
OTH SYMPTOMS AND SIGNS
INVOLVING THE CIRC AND RESP SYS |
155 |
1678606.11 |
R10 |
ABDOMINAL AND PELVIC
PAIN |
331 |
3450124.21 |
R11 |
NAUSEA AND VOMITING |
314 |
3349551.08 |
R12 |
HEARTBURN |
216 |
2158854.77 |
R19 |
OTH SYMPTOMS AND SIGNS
INVOLVING THE DGSTV SYS AND ABDOMEN |
119 |
1164697.46 |
R20 |
DISTURBANCES OF SKIN
SENSATION |
68 |
549336.70 |
R21 |
RASH AND OTHER
NONSPECIFIC SKIN ERUPTION |
340 |
3547349.53 |
R22 |
LOCALIZED SWELLING,
MASS AND LUMP OF SKIN, SUBCU |
104 |
1351030.86 |
R25 |
ABNORMAL INVOLUNTARY
MOVEMENTS |
143 |
1161474.31 |
R26 |
ABNORMALITIES OF GAIT
AND MOBILITY |
89 |
830061.49 |
R32 |
UNSPECIFIED URINARY
INCONTINENCE |
199 |
1826859.82 |
R35 |
POLYURIA |
70 |
721162.52 |
R39 |
OTH AND UNSP SYMPTOMS
AND SIGNS INVOLVING THE GU SYS |
71 |
730519.35 |
R41 |
OTH SYMPTOMS AND SIGNS
W COGNITIVE FUNCTIONS AND AWARENESS |
166 |
1628994.13 |
R42 |
DIZZINESS AND
GIDDINESS |
327 |
3038004.99 |
R45 |
SYMPTOMS AND SIGNS
INVOLVING EMOTIONAL STATE |
44 |
422460.58 |
R47 |
SPEECH DISTURBANCES,
NOT ELSEWHERE CLASSIFIED |
65 |
676117.29 |
R50 |
FEVER OF OTHER AND
UNKNOWN ORIGIN |
126 |
1634257.43 |
R51 |
HEADACHE |
202 |
2038393.95 |
R52 |
PAIN, UNSPECIFIED |
232 |
1768336.39 |
R53 |
MALAISE AND FATIGUE |
147 |
1451001.92 |
R54 |
AGE-RELATED PHYSICAL
DEBILITY |
120 |
1110548.85 |
R55 |
SYNCOPE AND COLLAPSE |
53 |
508076.92 |
R56 |
CONVULSIONS, NOT
ELSEWHERE CLASSIFIED |
150 |
1361090.47 |
R60 |
EDEMA, NOT ELSEWHERE
CLASSIFIED |
563 |
4816508.44 |
R63 |
SYMPTOMS AND SIGNS
CONCERNING FOOD AND FLUID INTAKE |
95 |
824417.24 |
R73 |
ELEVATED BLOOD GLUCOSE
LEVEL |
303 |
3104224.26 |
R87 |
ABNORMAL FINDINGS IN
SPECIMENS FROM FEMALE GENITAL ORGANS |
55 |
575094.39 |
R91 |
ABNORMAL FINDINGS ON
DIAGNOSTIC IMAGING OF LUNG |
63 |
697927.55 |
R97 |
ABNORMAL TUMOR MARKERS |
45 |
443694.63 |
S01 |
OPEN WOUND OF HEAD |
45 |
498244.60 |
S06 |
INTRACRANIAL INJURY |
73 |
813238.36 |
S09 |
OTHER AND UNSPECIFIED
INJURIES OF HEAD |
72 |
796023.26 |
S22 |
FRACTURE OF RIB(S),
STERNUM AND THORACIC SPINE |
41 |
438390.09 |
S32 |
FRACTURE OF LUMBAR
SPINE AND PELVIS |
62 |
498869.36 |
S39 |
OTH & UNSP INJURIES OF
ABD, LOW BACK, PELV & EXTRN GENITALS |
233 |
2751684.96 |
S42 |
FRACTURE OF SHOULDER
AND UPPER ARM |
99 |
1082279.38 |
S46 |
INJURY OF MUSCLE,
FASCIA AND TENDON AT SHLDR/UP ARM |
88 |
929845.11 |
S49 |
OTHER AND UNSPECIFIED
INJURIES OF SHOULDER AND UPPER ARM |
136 |
1317154.54 |
S61 |
OPEN WOUND OF WRIST,
HAND AND FINGERS |
83 |
1023166.06 |
S62 |
FRACTURE AT WRIST AND
HAND LEVEL |
129 |
1477685.63 |
S63 |
DISLOCATION AND SPRAIN
OF JOINTS AND LIGAMENTS AT WRS/HND LV |
42 |
448508.48 |
S69 |
OTHER AND UNSPECIFIED
INJURIES OF WRIST, HAND AND FINGER(S) |
102 |
1381664.31 |
S72 |
FRACTURE OF FEMUR |
42 |
490558.41 |
S82 |
FRACTURE OF LOWER LEG,
INCLUDING ANKLE |
128 |
1694149.71 |
S83 |
DISLOCATION AND SPRAIN
OF JOINTS AND LIGAMENTS OF KNEE |
119 |
1210701.71 |
S89 |
OTHER AND UNSPECIFIED
INJURIES OF LOWER LEG |
142 |
1484705.99 |
S92 |
FRACTURE OF FOOT AND
TOE, EXCEPT ANKLE |
101 |
1039620.60 |
S93 |
DISLOC & SPRAIN OF
JOINTS & LIGAMENTS AT ANKL, FT & TOE LEV |
116 |
1306585.95 |
S99 |
OTHER AND UNSPECIFIED
INJURIES OF ANKLE AND FOOT |
100 |
1341590.74 |
T14 |
INJURY OF UNSPECIFIED
BODY REGION |
377 |
4225668.96 |
T63 |
TOXIC EFFECT OF
CONTACT WITH VENOMOUS ANIMALS AND PLANTS |
102 |
1122084.62 |
T78 |
ADVERSE EFFECTS, NOT
ELSEWHERE CLASSIFIED |
656 |
6276512.11 |
T88 |
OTH COMPLICATIONS OF
SURGICAL AND MEDICAL CARE, NEC |
69 |
661363.68 |
U07 |
EMERGENCY USE OF U07 |
1695 |
21056866.35 |
Z00 |
ENCNTR FOR GENERAL
EXAM W/O COMPLAINT, SUSP OR REPRTD DX |
309 |
3764860.70 |
Z01 |
ENCNTR FOR OTH SP EXAM
W/O COMPLAINT, SUSPECTED OR REPRTD DX |
256 |
2538813.38 |
Z04 |
ENCOUNTER FOR
EXAMINATION AND OBSERVATION FOR OTHER REASONS |
93 |
915741.28 |
Z12 |
ENCOUNTER FOR
SCREENING FOR MALIGNANT NEOPLASMS |
322 |
3324155.37 |
Z13 |
ENCOUNTER FOR
SCREENING FOR OTHER DISEASES AND DISORDERS |
400 |
3231442.18 |
Z20 |
CONTACT W AND
(SUSPECTED) EXPOSURE TO COMMUNICABLE DISEASES |
2117 |
28244441.99 |
Z21 |
ASYMPTOMATIC HUMAN
IMMUNODEFICIENCY VIRUS INFECTION STATUS |
75 |
619663.70 |
Z23 |
ENCOUNTER FOR
IMMUNIZATION |
2448 |
29080545.70 |
Z29 |
ENCOUNTER FOR OTHER
PROPHYLACTIC MEASURES |
132 |
1409829.49 |
Z30 |
ENCOUNTER FOR
CONTRACEPTIVE MANAGEMENT |
450 |
6574003.91 |
Z34 |
ENCOUNTER FOR
SUPERVISION OF NORMAL PREGNANCY |
312 |
3962987.98 |
Z38 |
LIVEBORN INFANTS
ACCORDING TO PLACE OF BIRTH AND TYPE OF DEL |
53 |
870585.24 |
Z45 |
ENCOUNTER FOR
ADJUSTMENT AND MANAGEMENT OF IMPLANTED DEVICE |
48 |
440046.06 |
Z51 |
ENCOUNTER FOR OTHER
AFTERCARE AND MEDICAL CARE |
66 |
590198.28 |
Z63 |
OTH PROB REL TO PRIM
SUPPORT GROUP, INC FAMILY CIRCUMSTANCES |
63 |
724066.89 |
Z71 |
PERSONS ENCNTR HEALTH
SERV FOR OTH CNSL AND MED ADVICE, NEC |
253 |
2930457.17 |
Z76 |
PERSONS ENCOUNTERING
HEALTH SERVICES IN OTHER CIRCUMSTANCES |
244 |
2307686.06 |
Z79 |
LONG TERM (CURRENT)
DRUG THERAPY |
409 |
3966341.57 |
Z90 |
ACQUIRED ABSENCE OF
ORGANS, NOT ELSEWHERE CLASSIFIED |
50 |
559867.94 |
Z91 |
PERSONAL RISK FACTORS,
NOT ELSEWHERE CLASSIFIED |
82 |
1048130.70 |
Z95 |
PRESENCE OF CARDIAC
AND VASCULAR IMPLANTS AND GRAFTS |
103 |
992734.93 |
Z96 |
PRESENCE OF OTHER
FUNCTIONAL IMPLANTS |
243 |
2350559.92 |
Z97 |
PRESENCE OF OTHER
DEVICES |
86 |
813666.87 |
|
|
94641 |
984161434.18 |
Return To Table Of Contents
Table 2 UNWEIGHTED AND WEIGHTED COUNT OF RECORDS FOR EACH VALUE OF CCSR COMBINATION
CCSR1X VALUE |
CCSR1X LABEL |
CCSR2X VALUE |
CCSR2X LABEL |
CCSR3X VALUE |
CCSR3X LABEL |
UNWEIGHTED |
WEIGHTED BY perwt21f |
-15 |
CANNOT BE COMPUTED |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
472 |
4498471.22 |
BLD000 |
DISEASES OF BLOOD AND
DISORDERS INVOLVING
IMMUNE MECHANIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
147 |
1455608.31 |
BLD000 |
DISEASES OF BLOOD AND
DISORDERS INVOLVING
IMMUNE MECHANIS |
CIR000 |
DISEASES OF THE
CIRCULATORY
SYSTEM |
-1 |
INAPPLICABLE |
1 |
10889.00 |
BLD000 |
DISEASES OF BLOOD AND
DISORDERS INVOLVING
IMMUNE MECHANIS |
INJ000 |
INJURY, POISONING &
CERTAIN
OTH CONSEQUENCES OF EXTNL
CAU |
-1 |
INAPPLICABLE |
1 |
26110.31 |
BLD000 |
DISEASES OF BLOOD AND
DISORDERS INVOLVING
IMMUNE MECHANIS |
NEO000 |
NEOPLASMS |
-1 |
INAPPLICABLE |
4 |
59926.20 |
BLD001 |
NUTRITIONAL ANEMIA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
104 |
1022061.64 |
BLD003 |
APLASTIC ANEMIA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
178 |
1689988.74 |
BLD008 |
IMMUNITY DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
42 |
452854.04 |
CIR000 |
DISEASES OF THE
CIRCULATORY SYSTEM |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
363 |
3506496.18 |
CIR000 |
DISEASES OF THE
CIRCULATORY SYSTEM |
FAC000 |
FACTORS INFLUENCING
HEALTH
STATUS & CONTACT W/ HEALTH
SER |
-1 |
INAPPLICABLE |
21 |
202401.06 |
CIR000 |
DISEASES OF THE
CIRCULATORY SYSTEM |
GEN000 |
DISEASES OF THE
GENITOURINARY SYSTEM |
-1 |
INAPPLICABLE |
1 |
4760.58 |
CIR000 |
DISEASES OF THE
CIRCULATORY SYSTEM |
MUS000 |
DISEASES OF THE
MUSCULOSKELETAL SYSTEM AND
CONNECTIVE TIS |
-1 |
INAPPLICABLE |
5 |
56077.45 |
CIR003 |
NONRHEUMATIC AND
UNSPECIFIED VALVE
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
53 |
597308.80 |
CIR004 |
ENDOCARDITIS AND
ENDOCARDIAL DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
121 |
1243622.07 |
CIR007 |
ESSENTIAL HYPERTENSION |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
6593 |
62946340.94 |
CIR009 |
ACUTE MYOCARDIAL
INFARCTION |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
511 |
4769298.65 |
CIR011 |
CORONARY
ATHEROSCLEROSIS AND OTHER HEART
DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
1021 |
9549355.81 |
CIR011 |
CORONARY
ATHEROSCLEROSIS AND OTHER HEART
DISEASE |
FAC009 |
IMPLANT, DEVICE OR
GRAFT
RELATED ENCOUNTER |
-1 |
INAPPLICABLE |
59 |
587356.65 |
CIR012 |
NONSPECIFIC CHEST PAIN |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
212 |
2154975.68 |
CIR013 |
ACUTE PULMONARY
EMBOLISM |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
68 |
700268.15 |
CIR015 |
OTHER AND ILL-DEFINED
HEART DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
274 |
2442546.72 |
CIR016 |
CONDUCTION DISORDERS |
FAC009 |
IMPLANT, DEVICE OR
GRAFT
RELATED ENCOUNTER |
-1 |
INAPPLICABLE |
92 |
845424.34 |
CIR017 |
CARDIAC DYSRHYTHMIAS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
809 |
7826737.84 |
CIR019 |
HEART FAILURE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
208 |
1745406.48 |
CIR020 |
CEREBRAL INFARCTION |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
61 |
446907.01 |
CIR026 |
PERIPHERAL AND
VISCERAL VASCULAR DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
55 |
547698.26 |
CIR029 |
AORTIC; PERIPHERAL;
AND VISCERAL ARTERY
ANEURYSMS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
62 |
454611.01 |
CIR030 |
AORTIC AND PERIPHERAL
ARTERIAL EMBOLISM OR
THROMBOSIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
356 |
3261653.40 |
CIR031 |
HYPOTENSION |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
77 |
822389.89 |
CIR032 |
OTHER SPECIFIED AND
UNSPECIFIED CIRCULATORY
DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
92 |
717184.50 |
CIR035 |
VARICOSE VEINS OF
LOWER EXTREMITY |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
50 |
669244.18 |
CIR039 |
OTHER SPECIFIED
DISEASES OF VEINS AND
LYMPHATICS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
41 |
429358.25 |
DIG000 |
DISEASES OF THE
DIGESTIVE SYSTEM |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
325 |
3479865.42 |
DIG000 |
DISEASES OF THE
DIGESTIVE SYSTEM |
INF000 |
CERTAIN INFECTIOUS AND
PARASITIC DISEASES |
-1 |
INAPPLICABLE |
70 |
868001.86 |
DIG000 |
DISEASES OF THE
DIGESTIVE SYSTEM |
INJ000 |
INJURY, POISONING &
CERTAIN
OTH CONSEQUENCES OF EXTNL
CAU |
-1 |
INAPPLICABLE |
1 |
20233.25 |
DIG000 |
DISEASES OF THE
DIGESTIVE SYSTEM |
MUS000 |
DISEASES OF THE
MUSCULOSKELETAL SYSTEM AND
CONNECTIVE TIS |
-1 |
INAPPLICABLE |
3 |
41820.88 |
DIG000 |
DISEASES OF THE
DIGESTIVE SYSTEM |
NEO000 |
NEOPLASMS |
-1 |
INAPPLICABLE |
7 |
66506.46 |
DIG000 |
DISEASES OF THE
DIGESTIVE SYSTEM |
SYM000 |
SYMPTOMS, SIGNS AND
ABNORMAL CLINICAL & LAB
FINDINGS, NEC |
-1 |
INAPPLICABLE |
14 |
147497.74 |
DIG001 |
INTESTINAL INFECTION |
INF008 |
VIRAL INFECTION |
-1 |
INAPPLICABLE |
89 |
1095817.67 |
DIG001 |
INTESTINAL INFECTION |
INF009 |
PARASITIC, OTHER
SPECIFIED
AND UNSPECIFIED INFECTIONS |
-1 |
INAPPLICABLE |
42 |
504042.34 |
DIG002 |
DISORDERS OF TEETH AND
GINGIVA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
588 |
6699419.38 |
DIG003 |
DISEASES OF MOUTH;
EXCLUDING DENTAL |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
56 |
561381.61 |
DIG004 |
ESOPHAGEAL DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
1866 |
18383555.02 |
DIG005 |
GASTRODUODENAL ULCER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
70 |
581823.17 |
DIG007 |
GASTRITIS AND
DUODENITIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
137 |
982639.64 |
DIG008 |
OTH SPECIFIED &
UNSPECIFIED DISORDERS OF
STOMACH & DUODEN |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
386 |
3641847.43 |
DIG010 |
ABDOMINAL HERNIA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
230 |
2285522.28 |
DIG011 |
REGIONAL ENTERITIS AND
ULCERATIVE COLITIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
57 |
718287.99 |
DIG013 |
DIVERTICULOSIS AND
DIVERTICULITIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
100 |
895385.63 |
DIG014 |
HEMORRHOIDS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
85 |
835691.73 |
DIG017 |
BILIARY TRACT DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
148 |
1443281.44 |
DIG019 |
OTHER SPECIFIED AND
UNSPECIFIED LIVER DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
157 |
1544210.90 |
DIG021 |
GASTROINTESTINAL
HEMORRHAGE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
57 |
547900.58 |
DIG022 |
NONINFECTIOUS
GASTROENTERITIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
59 |
475886.99 |
DIG025 |
OTHER SPECIFIED AND
UNSPECIFIED
GASTROINTESTINAL DISORDER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
682 |
6546875.76 |
EAR000 |
DISEASES OF THE EAR
AND MASTOID PROCESS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
84 |
1095091.29 |
EAR000 |
DISEASES OF THE EAR
AND MASTOID PROCESS |
INJ000 |
INJURY, POISONING &
CERTAIN
OTH CONSEQUENCES OF EXTNL
CAU |
-1 |
INAPPLICABLE |
1 |
17350.95 |
EAR001 |
OTITIS MEDIA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
379 |
4942547.98 |
EAR004 |
HEARING LOSS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
324 |
3363277.00 |
EAR006 |
OTHER SPECIFIED AND
UNSPECIFIED DISORDERS OF
THE EAR |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
298 |
3463123.57 |
END000 |
ENDOCRINE, NUTRITIONAL
AND METABOLIC
DISEASES |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
97 |
1056425.01 |
END000 |
ENDOCRINE, NUTRITIONAL
AND METABOLIC
DISEASES |
EYE000 |
DISEASES OF THE EYE
AND
ADNEXA |
-1 |
INAPPLICABLE |
29 |
266808.70 |
END000 |
ENDOCRINE, NUTRITIONAL
AND METABOLIC
DISEASES |
GEN000 |
DISEASES OF THE
GENITOURINARY SYSTEM |
-1 |
INAPPLICABLE |
9 |
78279.47 |
END000 |
ENDOCRINE, NUTRITIONAL
AND METABOLIC
DISEASES |
NVS000 |
DISEASES OF THE
NERVOUS
SYSTEM |
-1 |
INAPPLICABLE |
2 |
11227.87 |
END000 |
ENDOCRINE, NUTRITIONAL
AND METABOLIC
DISEASES |
SKN000 |
DISEASES OF THE SKIN
AND
SUBCUTANEOUS TISSUE |
-1 |
INAPPLICABLE |
9 |
79194.44 |
END001 |
THYROID DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
2116 |
22157477.12 |
END002 |
DIABETES MELLITUS
WITHOUT COMPLICATION |
END005 |
DIABETES MELLITUS,
TYPE 2 |
-1 |
INAPPLICABLE |
2957 |
27139537.15 |
END003 |
DIABETES MELLITUS WITH
COMPLICATION |
END005 |
DIABETES MELLITUS,
TYPE 2 |
NVS020 |
OTHER SPECIFIED
NERVOUS SYSTEM
DISORDERS |
68 |
679718.77 |
END007 |
NUTRITIONAL
DEFICIENCIES |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
840 |
8465250.27 |
END009 |
OBESITY |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
112 |
1225780.32 |
END010 |
DISORDERS OF LIPID
METABOLISM |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
5010 |
48579855.91 |
END011 |
FLUID AND ELECTROLYTE
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
470 |
3966580.06 |
END015 |
OTHER SPECIFIED AND
UNSPECIFIED ENDOCRINE
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
272 |
3263964.65 |
END016 |
OTH SPECIFIED & UNSPEC
NUTRITIONAL AND
METABOLIC DISORDER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
145 |
1436804.12 |
EXT000 |
EXTERNAL CAUSES OF
MORBIDITY |
INJ000 |
INJURY, POISONING &
CERTAIN
OTH CONSEQUENCES OF EXTNL
CAU |
-1 |
INAPPLICABLE |
1 |
5057.41 |
EYE000 |
DISEASES OF THE EYE
AND ADNEXA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
144 |
1739522.62 |
EYE000 |
DISEASES OF THE EYE
AND ADNEXA |
INF000 |
CERTAIN INFECTIOUS AND
PARASITIC DISEASES |
-1 |
INAPPLICABLE |
2 |
13729.16 |
EYE001 |
CORNEA AND EXTERNAL
DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
141 |
1773739.18 |
EYE002 |
CATARACT AND OTHER
LENS DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
764 |
6634104.39 |
EYE003 |
GLAUCOMA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
555 |
5013149.20 |
EYE004 |
UVEITIS AND OCULAR
INFLAMMATION |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
100 |
1032961.66 |
EYE005 |
RETINAL AND VITREOUS
CONDITIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
462 |
4309670.22 |
EYE008 |
OCULOFACIAL PLASTICS
AND ORBITAL CONDITIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
347 |
3322219.03 |
EYE009 |
REFRACTIVE ERROR |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
418 |
5219342.11 |
EYE010 |
BLINDNESS AND VISION
DEFECTS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
296 |
3035081.01 |
EYE012 |
OTHER SPECIFIED EYE
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
250 |
2481520.58 |
FAC000 |
FACTORS INFLUENCING
HEALTH STATUS &
CONTACT W/ HEALTH SER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
373 |
4363428.12 |
FAC003 |
ENCTR FOR OBS, EXAM
COND R/O, EXCL INFECT
DIS, NPL, MENT |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
493 |
4147183.46 |
FAC005 |
ENCOUNTER FOR
PROPHYLACTIC MEASURES
(EXCLUDES IMMUNIZATIO |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
132 |
1409829.49 |
FAC008 |
NEOPLASM-RELATED
ENCOUNTERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
322 |
3324155.37 |
FAC009 |
IMPLANT, DEVICE OR
GRAFT RELATED ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
438 |
4283586.08 |
FAC010 |
OTHER AFTERCARE
ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
144 |
1399178.52 |
FAC012 |
OTHER SPECIFIED
ENCOUNTERS AND COUNSELING |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
497 |
5238143.23 |
FAC013 |
CONTRACEPTIVE AND
PROCREATIVE
MANAGEMENT |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
450 |
6574003.91 |
FAC014 |
MEDICAL
EXAMINATION/EVALUATION |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
565 |
6303674.08 |
FAC016 |
EXPOSURE, ENCTR,
SCREENING OR CONTACT W/
INFECTIOUS DISEA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
4565 |
57324987.69 |
FAC019 |
SOCIOECONOMIC/PSYCHOSOCIAL FACTORS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
63 |
724066.89 |
FAC022 |
ACQUIRED ABSENCE OF
LIMB OR ORGAN |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
50 |
559867.94 |
FAC025 |
OTHER SPECIFIED STATUS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
389 |
3879329.35 |
GEN000 |
DISEASES OF THE
GENITOURINARY SYSTEM |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
205 |
2409373.22 |
GEN000 |
DISEASES OF THE
GENITOURINARY SYSTEM |
INF000 |
CERTAIN INFECTIOUS AND
PARASITIC DISEASES |
-1 |
INAPPLICABLE |
5 |
106297.86 |
GEN000 |
DISEASES OF THE
GENITOURINARY SYSTEM |
INJ000 |
INJURY, POISONING &
CERTAIN
OTH CONSEQUENCES OF EXTNL
CAU |
-1 |
INAPPLICABLE |
1 |
9526.52 |
GEN001 |
NEPHRITIS; NEPHROSIS;
RENAL SCLEROSIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
49 |
507852.21 |
GEN002 |
ACUTE AND UNSPECIFIED
RENAL FAILURE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
93 |
742830.54 |
GEN003 |
CHRONIC KIDNEY DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
66 |
639699.72 |
GEN004 |
URINARY TRACT
INFECTIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
807 |
8273877.67 |
GEN005 |
CALCULUS OF URINARY
TRACT |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
224 |
2459467.27 |
GEN006 |
OTH SPECIFIED AND
UNSPECIFIED DISEASES OF
KIDNEY AND URET |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
341 |
2912870.50 |
GEN007 |
OTH SPECIFIED &
UNSPECIFIED DISEASES OF
BLADDER AND URETH |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
203 |
2071200.69 |
GEN008 |
URINARY INCONTINENCE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
199 |
1826859.82 |
GEN012 |
HYPERPLASIA OF
PROSTATE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
394 |
3953015.47 |
GEN013 |
INFLAMMATORY
CONDITIONS OF MALE GENITAL
ORGANS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
45 |
467662.13 |
GEN014 |
ERECTILE DYSFUNCTION |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
110 |
1387973.15 |
GEN016 |
OTHER SPECIFIED MALE
GENITAL DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
220 |
2331115.62 |
GEN017 |
NONMALIGNANT BREAST
CONDITIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
171 |
1846446.20 |
GEN018 |
INFLAMMATORY DISEASES
OF FEMALE PELVIC
ORGANS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
42 |
492605.55 |
GEN018 |
INFLAMMATORY DISEASES
OF FEMALE PELVIC
ORGANS |
GEN025 |
OTHER SPECIFIED FEMALE
GENITAL DISORDERS |
INF004 |
FUNGAL INFECTIONS |
67 |
831639.64 |
GEN019 |
ENDOMETRIOSIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
39 |
500030.33 |
GEN020 |
PROLAPSE OF FEMALE
GENITAL ORGANS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
46 |
430268.08 |
GEN021 |
MENSTRUAL DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
174 |
2437072.10 |
GEN022 |
BENIGN OVARIAN CYST |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
64 |
815388.28 |
GEN023 |
MENOPAUSAL DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
285 |
3197330.78 |
GEN025 |
OTHER SPECIFIED FEMALE
GENITAL DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
150 |
1896726.58 |
INF000 |
CERTAIN INFECTIOUS AND
PARASITIC DISEASES |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
159 |
1652190.55 |
INF000 |
CERTAIN INFECTIOUS AND
PARASITIC DISEASES |
MUS000 |
DISEASES OF THE
MUSCULOSKELETAL SYSTEM AND
CONNECTIVE TIS |
-1 |
INAPPLICABLE |
10 |
79565.06 |
INF000 |
CERTAIN INFECTIOUS AND
PARASITIC DISEASES |
NVS000 |
DISEASES OF THE
NERVOUS
SYSTEM |
-1 |
INAPPLICABLE |
4 |
37063.61 |
INF000 |
CERTAIN INFECTIOUS AND
PARASITIC DISEASES |
PNL000 |
CERTAIN CONDITIONS
ORIGINATING IN THE PERINATAL
PERIOD |
-1 |
INAPPLICABLE |
4 |
70603.18 |
INF000 |
CERTAIN INFECTIOUS AND
PARASITIC DISEASES |
RSP000 |
DISEASES OF THE
RESPIRATORY
SYSTEM |
-1 |
INAPPLICABLE |
5 |
30185.16 |
INF000 |
CERTAIN INFECTIOUS AND
PARASITIC DISEASES |
SKN000 |
DISEASES OF THE SKIN
AND
SUBCUTANEOUS TISSUE |
-1 |
INAPPLICABLE |
7 |
70110.29 |
INF003 |
BACTERIAL INFECTIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
106 |
1350364.55 |
INF003 |
BACTERIAL INFECTIONS |
RSP006 |
OTHER SPECIFIED UPPER
RESPIRATORY INFECTIONS |
-1 |
INAPPLICABLE |
164 |
2390277.82 |
INF004 |
FUNGAL INFECTIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
321 |
3367996.49 |
INF006 |
HIV INFECTION |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
75 |
619663.70 |
INF008 |
VIRAL INFECTION |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
378 |
4383148.08 |
INF008 |
VIRAL INFECTION |
SKN007 |
OTHER SPECIFIED AND
UNSPECIFIED SKIN DISORDERS |
-1 |
INAPPLICABLE |
87 |
948273.04 |
INF009 |
PARASITIC, OTHER
SPECIFIED AND UNSPECIFIED
INFECTIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
99 |
1038852.18 |
INF012 |
CORONAVIRUS DISEASE -
2019 (COVID-19) |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
1695 |
21056866.35 |
INJ000 |
INJURY, POISONING &
CERTAIN OTH
CONSEQUENCES OF EXTNL CAU |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
288 |
3132518.36 |
INJ000 |
INJURY, POISONING &
CERTAIN OTH
CONSEQUENCES OF EXTNL CAU |
MBD000 |
MENTAL, BEHAVIORAL AND
NEURODEVELOPMENTAL
DISORDERS |
-1 |
INAPPLICABLE |
2 |
14544.33 |
INJ000 |
INJURY, POISONING &
CERTAIN OTH
CONSEQUENCES OF EXTNL CAU |
NVS000 |
DISEASES OF THE
NERVOUS
SYSTEM |
-1 |
INAPPLICABLE |
3 |
34819.80 |
INJ027 |
OTHER UNSPECIFIED
INJURY |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
91 |
1038462.78 |
INJ031 |
ALLERGIC REACTIONS |
RSP007 |
OTHER SPECIFIED AND
UNSPECIFIED UPPER
RESPIRATORY DISEASE |
-1 |
INAPPLICABLE |
989 |
10874173.45 |
INJ031 |
ALLERGIC REACTIONS |
SKN002 |
OTHER SPECIFIED
INFLAMMATORY CONDITION OF
SKIN |
-1 |
INAPPLICABLE |
51 |
608729.21 |
INJ031 |
ALLERGIC REACTIONS |
SKN005 |
CONTACT DERMATITIS |
-1 |
INAPPLICABLE |
124 |
1441216.74 |
INJ031 |
ALLERGIC REACTIONS |
SKN007 |
OTHER SPECIFIED AND
UNSPECIFIED SKIN DISORDERS |
-1 |
INAPPLICABLE |
278 |
3712889.32 |
INJ039 |
FRACTURE OF THE SPINE
AND BACK, SUBSEQUENT
ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
62 |
498869.36 |
INJ040 |
FRACTURE OF TORSO,
SUBSEQUENT ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
41 |
438390.09 |
INJ041 |
FRACTURE OF THE UPPER
LIMB, SUBSEQUENT
ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
228 |
2559965.01 |
INJ042 |
FRACTURE OF LOWER LIMB
(EXCEPT HIP),
SUBSEQUENT ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
229 |
2733770.30 |
INJ043 |
FRACTURE OF THE NECK
OF THE FEMUR (HIP),
SUBSEQUENT ENCTR |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
42 |
490558.41 |
INJ044 |
DISLOCATIONS,
SUBSEQUENT ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
44 |
418046.97 |
INJ045 |
TRAUMATIC BRAIN INJURY
(TBI); CONCUSSION,
SUBSEQUENT ENCT |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
73 |
813238.36 |
INJ048 |
OPEN WOUNDS OF HEAD
AND NECK, SUBSEQUENT
ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
45 |
498244.60 |
INJ049 |
OPEN WOUNDS TO LIMBS,
SUBSEQUENT
ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
123 |
1376222.91 |
INJ054 |
SUPERFICIAL INJURY;
CONTUSION, SUBSEQUENT
ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
73 |
897572.46 |
INJ060 |
TOXIC EFFECTS,
SUBSEQUENT ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
102 |
1122084.62 |
INJ061 |
SPRAINS AND STRAINS,
SUBSEQUENT ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
685 |
7847571.91 |
INJ064 |
OTHER UNSPECIFIED
INJURIES, SUBSEQUENT
ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
1073 |
11980897.27 |
INJ067 |
ALLERGIC REACTIONS,
SUBSEQUENT ENCOUNTER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
656 |
6276512.11 |
INJ072 |
COMPLC OF OTHER
SURGICAL/MEDICAL CARE,
INJURY, SUBSEQ ENC |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
69 |
661363.68 |
MAL000 |
CONGENITAL
MALFORMATIONS, DEFORMATIONS &
CHROMOSOMAL ABNO |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
95 |
1500574.92 |
MBD000 |
MENTAL, BEHAVIORAL AND
NEURODEVELOPMENTAL DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
224 |
2470150.27 |
MBD000 |
MENTAL, BEHAVIORAL AND
NEURODEVELOPMENTAL DISORDERS |
PRG000 |
PREGNANCY, CHILDBIRTH
AND
THE PUERPERIUM |
-1 |
INAPPLICABLE |
2 |
33681.27 |
MBD001 |
SCHIZOPHRENIA SPECTRUM
AND OTHER
PSYCHOTIC DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
82 |
680727.38 |
MBD002 |
DEPRESSIVE DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
2175 |
23268343.85 |
MBD003 |
BIPOLAR AND RELATED
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
310 |
2848383.61 |
MBD004 |
OTHER SPECIFIED AND
UNSPECIFIED MOOD
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
130 |
1314870.33 |
MBD005 |
ANXIETY AND
FEAR-RELATED DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
2547 |
28918769.46 |
MBD006 |
OBSESSIVE-COMPULSIVE
AND RELATED DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
57 |
751547.48 |
MBD007 |
TRAUMA- AND
STRESSOR-RELATED DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
542 |
5834748.31 |
MBD008 |
DISRUPTIVE,
IMPULSE-CONTROL AND CONDUCT
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
43 |
496735.14 |
MBD013 |
MISCELLANEOUS MENTAL
AND BEHAVIORAL
DISORDERS/CONDITIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
295 |
3201716.90 |
MBD014 |
NEURODEVELOPMENTAL
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
967 |
12441252.27 |
MBD017 |
ALCOHOL-RELATED
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
49 |
595371.61 |
MBD025 |
OTHER SPECIFIED
SUBSTANCE-RELATED DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
44 |
465718.57 |
MUS000 |
DISEASES OF THE
MUSCULOSKELETAL SYSTEM AND
CONNECTIVE TIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
227 |
2590080.43 |
MUS000 |
DISEASES OF THE
MUSCULOSKELETAL SYSTEM AND
CONNECTIVE TIS |
SKN000 |
DISEASES OF THE SKIN
AND
SUBCUTANEOUS TISSUE |
-1 |
INAPPLICABLE |
32 |
439353.47 |
MUS003 |
RHEUMATOID ARTHRITIS
AND RELATED DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
486 |
4049192.94 |
MUS006 |
OSTEOARTHRITIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
2000 |
17893589.27 |
MUS007 |
OTHER SPECIFIED JOINT
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
392 |
3685740.94 |
MUS009 |
TENDON AND SYNOVIAL
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
389 |
3906225.12 |
MUS010 |
MUSCULOSKELETAL PAIN,
NOT LOW BACK PAIN |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
2973 |
30465376.76 |
MUS011 |
SPONDYLOPATHIES/SPONDYLOARTHROPATHY
(INCLUDING INFECTIVE) |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
946 |
9516582.29 |
MUS011 |
SPONDYLOPATHIES/SPONDYLOARTHROPATHY
(INCLUDING INFECTIVE) |
MUS038 |
LOW BACK PAIN |
-1 |
INAPPLICABLE |
644 |
6680905.01 |
MUS013 |
OSTEOPOROSIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
274 |
2483407.86 |
MUS021 |
ACQUIRED FOOT
DEFORMITIES |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
85 |
921989.38 |
MUS022 |
SCOLIOSIS AND OTHER
POSTURAL DORSOPATHIC
DEFORMITIES |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
121 |
1401465.77 |
MUS024 |
SYSTEMIC LUPUS
ERYTHEMATOSUS AND
CONNECTIVE TISSUE DISORD |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
146 |
1454089.08 |
MUS025 |
OTHER SPECIFIED
CONNECTIVE TISSUE DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
897 |
9082515.42 |
MUS026 |
MUSCLE DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
222 |
2137930.97 |
MUS028 |
OTHER SPECIFIED BONE
DISEASE AND
MUSCULOSKELETAL DEFORMIT |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
318 |
2862903.18 |
MUS033 |
GOUT |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
386 |
3902358.47 |
MUS038 |
LOW BACK PAIN |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
401 |
4329366.71 |
NEO000 |
NEOPLASMS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
345 |
3459323.76 |
NEO000 |
NEOPLASMS |
NVS000 |
DISEASES OF THE
NERVOUS
SYSTEM |
-1 |
INAPPLICABLE |
4 |
28515.03 |
NEO015 |
GASTROINTESTINAL
CANCERS - COLORECTAL |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
80 |
728579.32 |
NEO022 |
RESPIRATORY CANCERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
95 |
913489.91 |
NEO025 |
SKIN CANCERS -
MELANOMA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
159 |
1670148.65 |
NEO026 |
SKIN CANCERS - BASAL
CELL CARCINOMA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
88 |
963909.38 |
NEO027 |
SKIN CANCERS -
SQUAMOUS CELL CARCINOMA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
77 |
826348.00 |
NEO028 |
SKIN CANCERS - ALL
OTHER TYPES |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
449 |
4425260.56 |
NEO030 |
BREAST CANCER - ALL
OTHER TYPES |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
256 |
2226561.45 |
NEO039 |
MALE REPRODUCTIVE
SYSTEM CANCERS -
PROSTATE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
210 |
2134646.69 |
NEO043 |
URINARY SYSTEM CANCERS
- BLADDER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
39 |
378755.95 |
NEO050 |
ENDOCRINE SYSTEM
CANCERS - THYROID |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
65 |
719299.61 |
NEO058 |
NON-HODGKIN LYMPHOMA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
42 |
460143.76 |
NEO064 |
LEUKEMIA - ALL OTHER
TYPES |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
67 |
597101.42 |
NEO072 |
NEOPLASMS OF
UNSPECIFIED NATURE OR
UNCERTAIN BEHAVIOR |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
240 |
2807473.36 |
NEO073 |
BENIGN NEOPLASMS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
364 |
4062962.85 |
NVS000 |
DISEASES OF THE
NERVOUS SYSTEM |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
136 |
1446670.52 |
NVS000 |
DISEASES OF THE
NERVOUS SYSTEM |
SYM000 |
SYMPTOMS, SIGNS AND
ABNORMAL CLINICAL & LAB
FINDINGS, NEC |
-1 |
INAPPLICABLE |
1 |
8937.27 |
NVS004 |
PARKINSON`S DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
70 |
779692.26 |
NVS005 |
MULTIPLE SCLEROSIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
71 |
829176.76 |
NVS006 |
OTH SPECIFIED
HEREDITARY & DEGENERATIVE
NERVOUS SYSTEM CO |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
49 |
549905.84 |
NVS006 |
OTH SPECIFIED
HEREDITARY & DEGENERATIVE
NERVOUS SYSTEM CO |
NVS016 |
SLEEP WAKE DISORDERS |
-1 |
INAPPLICABLE |
178 |
1627590.90 |
NVS009 |
EPILEPSY; CONVULSIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
290 |
3076306.31 |
NVS010 |
HEADACHE; INCLUDING
MIGRAINE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
582 |
6648344.80 |
NVS010 |
HEADACHE; INCLUDING
MIGRAINE |
SYM010 |
NERVOUS SYSTEM SIGNS
AND
SYMPTOMS |
-1 |
INAPPLICABLE |
202 |
2038393.95 |
NVS011 |
NEUROCOGNITIVE
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
168 |
1490548.35 |
NVS012 |
TRANSIENT CEREBRAL
ISCHEMIA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
350 |
3037137.78 |
NVS015 |
POLYNEUROPATHIES |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
344 |
3123390.75 |
NVS016 |
SLEEP WAKE DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
1550 |
15214610.93 |
NVS017 |
NERVE AND NERVE ROOT
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
377 |
3878405.64 |
NVS019 |
NERVOUS SYSTEM PAIN
AND PAIN SYNDROMES |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
392 |
3691649.98 |
NVS020 |
OTHER SPECIFIED
NERVOUS SYSTEM DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
45 |
423568.86 |
PNL000 |
CERTAIN CONDITIONS
ORIGINATING IN THE
PERINATAL PERIOD |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
9 |
145289.29 |
PNL001 |
LIVEBORN |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
53 |
870585.24 |
PRG000 |
PREGNANCY, CHILDBIRTH
AND THE PUERPERIUM |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
118 |
1380661.13 |
PRG000 |
PREGNANCY, CHILDBIRTH
AND THE PUERPERIUM |
SYM000 |
SYMPTOMS, SIGNS AND
ABNORMAL CLINICAL & LAB
FINDINGS, NEC |
-1 |
INAPPLICABLE |
1 |
10441.44 |
PRG029 |
UNCOMPLICATED
PREGNANCY, DELIVERY OR
PUERPERIUM |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
330 |
4121354.13 |
RSP000 |
DISEASES OF THE
RESPIRATORY SYSTEM |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
105 |
1187127.86 |
RSP001 |
SINUSITIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
518 |
6808221.11 |
RSP002 |
PNEUMONIA (EXCEPT THAT
CAUSED BY
TUBERCULOSIS) |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
279 |
2843204.02 |
RSP003 |
INFLUENZA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
158 |
1691895.02 |
RSP004 |
ACUTE AND CHRONIC
TONSILLITIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
44 |
567819.78 |
RSP005 |
ACUTE BRONCHITIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
219 |
2379075.79 |
RSP006 |
OTHER SPECIFIED UPPER
RESPIRATORY INFECTIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
509 |
6221716.66 |
RSP007 |
OTHER SPECIFIED AND
UNSPECIFIED UPPER
RESPIRATORY DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
299 |
3143866.29 |
RSP008 |
CHRONIC OBSTRUCTIVE
PULMONARY DISEASE AND
BRONCHIECTASIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
698 |
5476151.50 |
RSP009 |
ASTHMA |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
1824 |
18827277.46 |
RSP016 |
OTHER SPECIFIED AND
UNSPECIFIED LOWER
RESPIRATORY DISEASE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
207 |
2449636.59 |
SKN000 |
DISEASES OF THE SKIN
AND SUBCUTANEOUS TISSUE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
136 |
1627975.45 |
SKN001 |
SKIN AND SUBCUTANEOUS
TISSUE INFECTIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
359 |
3915711.57 |
SKN002 |
OTHER SPECIFIED
INFLAMMATORY CONDITION OF
SKIN |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
616 |
7888153.68 |
SKN007 |
OTHER SPECIFIED AND
UNSPECIFIED SKIN
DISORDERS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
1161 |
12795344.70 |
SYM000 |
SYMPTOMS, SIGNS AND
ABNORMAL CLINICAL &
LAB FINDINGS, NEC |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
136 |
1405483.11 |
SYM001 |
SYNCOPE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
53 |
508076.92 |
SYM002 |
FEVER |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
126 |
1634257.43 |
SYM004 |
NAUSEA AND VOMITING |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
314 |
3349551.08 |
SYM006 |
ABDOMINAL PAIN & OTHER
DIGESTIVE/ABDOMEN
SIGNS AND SYMPTO |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
704 |
7141767.28 |
SYM007 |
MALAISE AND FATIGUE |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
147 |
1451001.92 |
SYM008 |
SYMPTOMS OF MENTAL AND
SUBSTANCE USE
CONDITIONS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
44 |
422460.58 |
SYM010 |
NERVOUS SYSTEM SIGNS
AND SYMPTOMS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
431 |
4155891.42 |
SYM011 |
GENITOURINARY SIGNS
AND SYMPTOMS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
253 |
2539337.91 |
SYM012 |
CIRCULATORY SIGNS AND
SYMPTOMS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
474 |
4961124.91 |
SYM013 |
RESPIRATORY SIGNS AND
SYMPTOMS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
702 |
7329967.49 |
SYM014 |
SKIN/SUBCUTANEOUS
SIGNS AND SYMPTOMS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
512 |
5447717.08 |
SYM015 |
GENERAL
SENSATION/PERCEPTION SIGNS AND
SYMPTOMS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
327 |
3038004.99 |
SYM016 |
OTHER GENERAL SIGNS
AND SYMPTOMS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
1247 |
10821548.68 |
SYM017 |
ABNORMAL FINDINGS
WITHOUT DIAGNOSIS |
-1 |
INAPPLICABLE |
-1 |
INAPPLICABLE |
591 |
6087613.72 |
|
|
|
|
|
|
94641 |
984161434.18 |
Return To Table Of Contents
|